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Abstracts
2. ABSTRACT
2.1 ZUSAMMENFASSUNG IN DEUTSCH  
Seit der Entdeckung von Nucleic Acid hat die Molekularbiologie enorme 
Fortschritte gemacht und vieles erreicht. Trotz all dem, besteht immer noch 
eine Lücke zwischen dem klassich-traditionellen medizinischen Ansatz, und 
der Molekularen Welt. 
Inspiriert durch die riesigen Datenmengen, die durch die "omics"-geführten 
Techniken und die  "high-throughput" Techniken (HTTs)  entstanden sind, 
habe ich versucht ein Protokoll zu entwickeln, welches die Hürde zwischen 
der  phenomenlogogical  Medizin  und  der  Molekularmedizin  überbrücken 
soll,  und  somit  das  Labor  dem Patientenbett  etwas  näher  bringen  wird. 
Ausserdem finde  ich,  dass  es  dringend nötig  ist  die  wichtigsten  "omics" 
Wissenschaften -  Genomics und Proteomics  - miteinander  zu integrieren. 
Nucleic  Acid  Programmable  Protein  Arrays  (NAPPA)  können  dies 
erreichen,  durch  die  Verwendung  eines  "complex  mammalian  cell  free  
expression" Systems um die Proteine in situ zu erzeugen. Als Alternative zu 
"fluorescent-labelled"  Ansätzen,  kann  eine  neue  kennzeichnungsfreie 
Methode, die durch den kombinierten Einsatz von drei unabhängigen und 
komplementären  nanobiotechnologischen  Ansätzen  entsteht,  verwendet 
werden. 
Diese  Methode  mag  fähig  sein  das  Zusammenspiel  von  Gen-  und 
Proteinfunktionen,  Gen-Proteine,  Gen-Medikamente,  Protein-Proteine  und 
Protein-Medikamente  zu  analysieren.  Dies  wäre  sehr  Vorteilhaft  für  die 
personalisierte  Medizin.  Quartz  Micro  Circuit  Nanogravimetry  (QCM), 
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basierend  auf  Frequenz-  und  Zerstreuungsfaktoren,  Massenspektrometrie 
(MS) und Anodic Porous Alumina (APA) überwinden fürwahr die Grenzen
von "correlated  fluorescence  detection",  welches  darunter  leidet,  dass  es 
trotz  gründlichem  Waschen  im  Hintergrund  weiterhin  detektiert  werden 
kann. Ausserdem wird momentan daran gearbeitet ein "homogeneous and 
well  defined  bacterial  cell  free expression  system"  weiter  zu optimieren, 
welches  die  ambitionierten  Ziele  der  Quantifizierung  der  bestimmenden 
Gene und Protein Netzwerke im menschlichen Körper verwirklichen kann. 
Implikationen  für  die  personalisierte  Medizin  der  oben  erwähnten 
kennzeichnungsfreien Protein Arrays mit dem Einsatz verschiedener Test-
Gene und Proteine, werden in dieser PhD-Arbeit besprochen.   
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2.2 ABSTRACT IN ENGLISH
Since  the  discovery  of  the  nucleic  acid,  molecular  biology  has  made 
tremendous progresses, achieving a lot of results.
Despite this, there is still a gap between the classical and traditional medical 
approach and the molecular world. Inspired by the incredible wealth of data 
generated  by  the  "omics"-driven  techniques  and  the  “high-trouhgput  
technologies” (HTTs), I have tried to develop a protocol that could reduce 
the actually extant barrier between the phenomenological medicine and the 
molecular  medicine,  facilitating  a  translational  shift  from the  lab  to  the 
patient bedside. I also felt the urgent need to integrate the most important 
omics sciences, that is to say genomics and proteomics. 
Nucleic  Acid  Programmable  Protein  Arrays  (NAPPA)  can  do  this,  by 
utilizing  a  complex  mammalian  cell  free  expression  system  to  produce 
proteins in situ. In alternative to fluorescent-labeled approaches a new label 
free method, emerging from the combined utilization of three independent 
and  complementary  nanobiotechnological  approaches,  appears  capable  to 
analyze gene and protein function, gene-protein, gene-drug, protein-protein 
and  protein-drug  interactions  in  studies  promising  for  personalized 
medicine. Quartz Micro Circuit nanogravimetry (QCM), based on frequency 
and dissipation factor, mass spectrometry (MS) and anodic porous alumina 
(APA)  overcomes  indeed  the  limits  of  correlated  fluorescence  detection 
plagued by the background still present after extensive washes. Work is in 
progress to further optimize this approach a homogeneous and well defined 
bacterial cell free expression system able to realize the ambitious objective 
to quantify the regulatory gene and protein networks in humans. 
10
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Abstract
Implications for personalized medicine of the above label free protein array 
using different test genes and proteins are reported in this PhD thesis.
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3. NANOMEDICINE: DEFINITION AND MAIN GOALS
“Personalized  nanomedicine”  is  “broadly  defined  as  the  approach  of  
science  and  engineering  at  the  nanometer  scale”  toward  individualized, 
“biomedical  applications”  [Lee  et  al.,  2009].  In  the  next  decades,  it  is 
expected  to be a promising and formidable  tool  for a targeted and more 
rationale  therapeutics,  that really  fits individual  patient's  needs,  emerging 
from the combination of “personalized medicine” and “nanomedicine”.
“Personalized medicine” can be defined as “as the prescription of specific  
treatments  best  suited  for  an  individual,  taking  into  consideration  both  
genetic  and  other  factors  that  influence  the  response  to  therapy”  [Jain, 
2008].
“Nanomedicine”  can  be  defined  as  “the  interplay  of  Bioinformatics  and  
Nanotechnology  to  a  previously  unforeseeable  level”  [Nicolini,  2006; 
Nicolini, 2010; Nicolini and Pechkova, 2010a; Nicolini et al., 2012b].  
The integration of information obtained from both “ex vivo” and “in vivo” 
techniques [Lammers et al., 2012] enables a precise and rich picture of the 
disease, which is completely unprecedented.  
The  size  of  the  functional  elements  of  the  biological  systems  is  the 
fundamental nanometer scale, from whence the term “nanomedicine”, being 
the  level  at  which  nanomaterials  interact  with  molecules.  These 
nanomaterials  offer  many  advantages  with  respect  to  the  classical  and 
traditional materials, such as the small size, larger volume-to-surface ratio, 
and can be finely tuned and manipulated down to the scale of a cluster of 
atoms, in order to have specifically designed properties and unique features. 
The  main  objectives  of  personalized  nanomedicine  are:  diagnosis  (chip-
based  bioassays,  molecular  imaging),  therapy  (drug  delivery  and  drug 
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release),  and  prognosis  (biomarkers,  molecular  monitoring  and  risk 
assessment). 
These phases are  not  necessarily  separate,  but  can be harmonized into a 
coherent  framework,  and  for  example  diagnosis  and  therapy  can  be 
integrated  into  a  unique  step,  termed  as  “theranostics”  (which  is  a 
portmanteau  of  “therapy”  and  “diagnostics”)  [Özdemir  and  Cho,  2012; 
Ozdemir and Dove, 2012].  
It  should  be  emphasized  that,  before,  therapeutics  was  based  upon  and 
followed the diagnosis (for a certain kind of disease, a drug or a treatment), 
while nowadays, considering the fact that the same drug can exert different 
effects  on  different  patients,  the  relationship  between  therapeutics  and 
diagnosis  becomes  more  complex  and  mutual,  rather  than  univocal. 
Another ambitious goal is prevention, which can be attained diagnosing the 
disease  at  an  earlier  stage  or  delivering  chemopreventive  drugs  in  an 
effective way.
High-throughput  technologies  are  able  to  produce  a  wealth  of  data  and 
information,  that  act  as  a  link  between  the  molecular  level  (molecular 
medicine) and the classical and traditional  medical approach (the clinical 
and phenomenological medicine).
Thus, personalized nanomedicine differs from molecular medicine, in that it 
exploits a systems biology approach and a broader, holistic method, in order
to capture the networks and the pathways which lie behind a disease.
For  this  reason,  personalized  nanomedicine  is  called  also  “network 
medicine” [Barabási,  2007; Barabási et  al.,  2011; Chen and Butte,  2013; 
Chen et al., 2013; Piro, 2012; Roukos, 2013; Silverman and Loscalzo, 2012; 
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Silverman and Loscalzo, 2013; Smith et al., 2013] or “systems medicine” 
[Emmert-Streib and Dehmer, 2013; Jain, 2008].
While molecular medicine focuses and relies on point and discrete pieces of 
information (thus providing static information), omics science can capture 
the activity and expression variations.
It differs of course also from the traditional approach, which is one-size-fits-
all, while nanomedicine can be predictive, personalized and preventive (the 
so-called  “P4 model”,  introduced by Leroy Hood) [Auffray et  al.,  2010; 
Hood, 2013; Hood and Friend, 2011].
Within  this  new  framework,  data  integration  plays  a  major  role,  since 
integrated  genomics–proteomics  data  are  useful  for  finding  disease 
biomarkers [Boja et al., 2011; Faratian et al., 2009; Hanash and Taguchi, 
2011] and for providing a more precise diagnosis and prognosis in the frame 
of translational medicine, shifting from the lab to the patient bedside: they 
can give an added value to the clinical assessment of the patient, as well as 
they can even predict the risk of a not yet clinically observable disease. 
A very recent and complex publication [Allen et al., 2012] has advocated a 
more  sophisticated  approach  and  shown  that  iPOP  (integrative  personal 
Omics profile) resulting from the combination of different Omics-based data 
(namely,  genomics,  proteomics,  transcriptomics,  metabolomics  or 
metabonomics, and autoantibodyomics), extensively collected and covered 
for  a  period  of  14  months,  can  be  a  promising  approach  to  manage 
proactively individual  health:  dynamic information of how genes interact 
with environment and change their expression throughout the time could be 
extracted and correlated with clinical implications. In the specific case type-
2 diabetes was predicted much earlier than its clinical onset: thus medicine 
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can become quantitative, predictive and preventative [Marko-Varga et al., 
2007]. However, the traditional anamnesis and record of the medical history 
are not negligible.
The two approaches are in fact complementary, rather than exclusive, and 
the interpretation of omics-based data without properly incorporating them 
within a clinical assessment can be misleading.
Personalized nanomedicine “has the power of combining nanomedicine with  
clinical and molecular biomarkers ("OMICS" data) achieving an improved  
prognosis and disease management as well as individualized drug selection  
and dosage profiling to ensure maximal efficacy and safety” [Rosenblum 
and Peer, 2013].
Unfortunately,  at  the  moment,  further  integration  among  the  different 
omics-based  and  enabled  disciplines  is  still  under  development  since  a 
complete and coherent taxonomy of all the omics sciences is missing (from 
an ontological and semantic point of view), and the concept of metadata for 
omics has been only recently introduced [Ozdemir et al., 2014]. 
Diseases such as cancer, obesity and diabetes, transplanted organ rejection 
and  hypertension  are  complex  biological  phenomena,  being  sometimes 
highly heterogeneous among patients despite similar clinical features. In the 
last decades, patients can be affected by many chronic diseases [Lee et al., 
2008; Neale and Kendler, 1995] throwing classical therapeutic approaches 
into crisis. “Classical medicine” fails to achieve its goal to cure individuals, 
and also molecular approach-based medicine risks to be unsuccessful if it 
does not take into account individual variations of the same disease [Pearson 
and Fabbro, 2004].
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A network approach for molecular medicine is thus emerging [Faratian et 
al.,  2009; Janjić and Pržulj, 2012; Loscalzo,  2007; Loscalzo et al.,  2007; 
Piro,  2012]  in  order  to  find  precisely  the  target  for  an  optimized  drug 
therapy. An alternative strategy for cancer biomarker validation and cancer 
treatment based on the decoding of the serum proteins patterns is indeed 
emerging  and  the  technical  advancement  in  measurements  and  the 
information derived from system biology should permit to develop tailored 
treatment  of  personalized  medicine  in  the  future.  Moreover,  new 
developments in proteomics tools emerging from the combination of both 
microfluidic chips (like the microfluidic integrated approach for identifying 
protein isoforms, [Hughes et  al.,  2012]) and an ad hoc designed protein-
capture agents (like the SOMAmers in the SOMAscan technology, [Gold et 
al., 2012]) can make the dream of a comprehensive proteomics become true.
Inspired  by  these  recent  technical  and  technological  advancements,  in 
Figure 1 we introduce a protocol starting from the collection of patients' 
samples (saliva, blood, urine, biopsies or others) and from the analysis of 
the  differentially  expressed  genes  (DEGs) using  both  statistical  and not-
statistical  analyses with the Leader Genes algorithm [Sivozhelezov et al., 
2006] and our  in-house microarray scanner termed DNASER [Nicolini et 
al., 2006] approaches, that we introduced as tools for molecular genomics 
enabling the selection of few important highly interconnected genes. These 
ab  initio targeted  microarray-based  bioinformatics  and  nanogenomics 
[Nicolini,  2006]  lead  to  a  panel  of  few  identified  genes  that  can  be 
expressed in a cell-free environment thanks to Nucleic Acid Programmable 
Protein  Array  (NAPPA)  technologies  [LaBaer  et  Ramachandran,  2005; 
Nicolini et al.,  2012a; Nicolini et al.,  2012b; Ramachandran et al.,  2008] 
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which utilizes a complex mammalian cell free expression system to produce 
proteins  in situ. In alternative to  fluorescently-labeled approaches, a wide 
range  of  nanotechnological  approaches  have  been  recently  introduced  to 
characterize  NAPPA  microarrays.  Label-free  NAPPA  technology,  in 
combination  with  drug nanodelivery  [Garibaldi  et  al.,  2006]  and protein 
nanobiocrystallography  [Pechkova  and  Nicolini,  2004;  Pechkova  and 
Riekel, 2011] and its possible ongoing developments using anodic porous 
alumina (APA) and bacterial cell-free expression system, appear to form a 
single approach, named “nanoproteomics” [Nicolini and Pechkova, 2010a; 
Nicolini and Pechkova, 2010b], capable of effectively solving the numerous 
problems still present in medical diagnosis and therapy.
The emerging label free NAPPA method [Nicolini and Pechkova, 2010a; 
Nicolini  and  Pechkova,  2010b]  consists  of  the  combined  utilization  of 
Quartz Crystal Microbalance based on the D-factor monitoring (QCM_D) 
nanogravimetry,  mass spectrometry (MS) and APA as the last step of the 
protocol for personalized medicine (Figure 1) being optimal in analyzing 
protein function and protein–protein interaction. Target protein microarrays 
provide  a  powerful  tool  for  high-throughput  technology-based  (HTT) 
analysis  of  protein–protein  or  small   molecules–protein  interactions. 
“Common  protein  microarrays  are  generated  by  separately  spotting  
purified  protein  on  the  arrays  with  a  linkage   chemistry”  [Spera  et  al., 
2013]. 
“However,  due  to  the  complicated  work  associated  with  HTT  protein  
production and purification, and the concerns regarding protein stability  
during storage before and after being spotted on the array, a significant 
improvement to the target protein micro-arrays is represented by NAPPA  
17
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which allows for functional proteins to be synthesized in situ directly from 
printed complementary DNAs (cDNAs) just in time for assay” [LaBaer and 
Ramachandran,  2005;  Nicolini  et  al.,  2012a;  Nicolini  et  al.,  2012b; 
Ramachandran et al., 2008]. 
“Printing cDNA, rather than proteins, eliminates the need to express and  
purify  proteins  separately  and  produces  proteins  “just-in-time”  for  the  
assay,  abrogating  concerns  about  protein  stability  during  storage” 
[Andersson et al., 2011; Ramachandran et al., 2004; Ramachandran et al., 
2005].  Label  free  nanotechnologies,  previously  used  to  study  molecular 
interaction  and adsorption  of  different  biomolecules,  are  here  applied  to 
functionalized  NAPPA  surfaces  [Garibaldi  et  al.,  2006;  Nicolini  and 
LaBaer,  2010;  Nicolini  and  Pechkova,  2010a;  Nicolini  and  Pechkova, 
2010b; Pechkova and Nicolini, 2004; Pechkova and Riekel, 2011] to enable 
the detection of proteins and their interactions without the need for labeling 
reagents with tags. 
18
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The  detection  of  low-abundant  biomarkers  from  biological  fluids  (e.g., 
blood, urine, saliva, or biopsies) requires HTT detection techniques and in 
this  sense  nanoproteomics  provides  the  robust  analytical  platform  for 
personalized  medicine,  as  needed  for  real-time  and  label-free  sensitive 
detection of low-abundant proteins [Nicolini and Pechkova, 2010a; Nicolini 
and Pechkova,  2010b]. Usually, in traditional labeling methods used in both 
nanogenomics and nanoproteomics a  fluorescent molecule is bound to the 
query  protein  by  a  linking  molecule,  mainly  an  antibody;  the  labeled 
molecule is then detected via a fluorescence microscope, flow cytometer or 
some other   fluorescence reading instrument  such as DNASER [Nicolini 
and Pechkova, 2010a; Nicolini and Pechkova, 2010b; Nicolini et al., 2002; 
Nicolini et al., 2006; Troitsky et al., 2002]. 
“This  kind  of  protein  array  fluorescence  analysis  presents  limitations  
particularly in the context of measuring naturally occurring ligands, such  
as in clinical studies where it is not possible to produce fusion proteins:  
namely the need to obtain a capture antibody for each analyzed protein,  
and the concern that a labeling molecule may alter the properties of the  
query  protein.  The  label  free  methods  here  utilized  for  the  analysis  of  
NAPPA  micro-array  then  represent  for  personalized  medicine  a  major  
advancement” [Nicolini et al., 2013b].
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Figure 1: the experimental approach developed for targeting issues in the  
field  of  personalized  nanomedicine  up  to  the  level  of  a  single  
physician/patient  relationship  (modified  from  [Nicolini,  Bragazzi  and  
Pechkova.  Nanoproteomics  enabling  personalized  nanomedicine.  
Advanced Drug Delivery Reviews, 2012])
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4. NANOGENOMICS
Nanogenomics  can  be  defined  as  a  discipline  combining 
nanobiotechnologies  and  genomics,  that  is  to  say  the  use  of  the  former 
techniques in order to get insights about gene regulation  [Nicolini,  2006; 
Nicolini, 2010; Nicolini and Pechkova, 2010].  
Nanogenomics   is  emerging  as  a  promising  discipline  in  the  field  of 
biomedicine, being the interplay of nanobiotechnologies and bioinformatics. 
Gene microarrays  and the other biomolecular  high-troughput  tools of the 
omics  sciences  (such  as  linkage  and  linkage  disequilibrium,  GWAS  or 
genome-wide  association  study,  QTL  or  quantitative  trait  loci  and  its 
derivative, such as eQTL, expression QTL, phenome profile, transcriptome 
analysis for genome mapping, and so on) [Jiang et al., 2012], can produce 
an incredible wealth of data.
A microarray is a high-troughput nanobiotechnology developed at Stanford 
in  the  nineties,  which  enables  the  simultaneous  measurement  of  a  vast 
number of genes or the genotyping of some genomic regions, and exploits 
the reverse hybridization process. It has as its precursor the Northern blot 
(developed in the seventies  by James  Alwine,  David Kemp,  and George 
Stark  at  Stanford  University).  It  is  a  solid-phase  assay and as  materials, 
glass, nylon, plastic or silicon chips can be used.  
If  on  one  hand,  these  “big  data”  [Marx,  2013;  Vivar  et  al.,  2013]  are 
necessary for  a  deep and profound underpinning of  the entire  molecular 
picture, which is extremely complex, on the other hand, researchers risk to 
be overwhelmed by these data, without a proper data reduction [Bragazzi 
and Nicolini, 2013]. 
For this reason, gene prioritization- or gene-ranking-based approaches have 
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been advocated as a fundamental task in bioinformatics, resulting in a list of 
few selected strong candidate genes, that can be further validated with  ad 
hoc targeted experiments. Underpinning genetic/genomics components and 
traits  is  particularly  demanding  and  challenging,  but  also  useful  when 
studying complex and multi-factorial diseases [Cohen and Hobbs, 2013; van 
Nas  et  al.,  2013],  such  as  Alzheimer’s  dementia  and  other  neurological 
pathologies  [Hallock  and  Thomas,  2012],  diabetes  and  other  metabolic 
disorders  [Jain  et  al.,  2013],  cancer  [Liu  et  al.,  2012],  neurological  and 
psychiatric diseases [Bragazzi, 2013], and cardiovascular disorders [King et 
al.,  2005].  Usually  these  diseases  are  chronic,  present  a  relatively  mild 
phenotype,  are slowly progressive, and have a tremendous burden for the 
society and impact on the population in term of quality of life (QOL). 
The  physio-pathology  of  complex  heterogeneous  pathologies  is 
characterized by various biologic pathways and networks, dependent upon 
the  contribution  of  a  large  number  of  genes  and  gene  products,  and 
therefore,  the  knowledge  of  molecular  mechanisms  of  complex  multi-
factorial diseases must include and deal with a large array of genes. These 
genes form complex networks of interactions, which may be direct (that is 
to  say,  physical  interactions  between  the  proteins,  confirmed  by 
experimental  techniques,  such  as  NMR  or  crystallography),  or  indirect 
(involvement  in  the  same  metabolic  pathway  or  co-expression  under 
different conditions). 
There are a lot  of gene-ranking methods,  which for example,  exploit  the 
Pearson  correlation  with  clinical  information  (such  as  the  Kaplan-Meier 
survival  time)  ([Jiang  et  al.,  2012]  and  references  therein;  [Goh  and 
Kasabov,  2005;  Muthuswami  et  al.,  2013]),  or  are  based  upon  gene 
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expression time series or  gene co-  expression series  [Odibat  and Reddy, 
2012], as derived from genome-wide association studies (GWAS), micro-
arrays, quantitative trait loci (QTL)/expression QTL (eQTL) analysis, single 
nucleotide polymorphisms (SNPs) and other mutations or from biomedical 
literature mining (ab initio approach), regulatory networks (protein-protein 
interaction, PPI [Gonçalvas et al., 2012; Guney and Oliva, 2012; Re et al., 
2012; Wang et al., 2013; Zheng and Zhao, 2012], gene-protein interaction, 
or  gene-gene  interaction  maps  [Vi  and  Ningron,  2012])  (for  further 
explanations and references, the reader is referred [Re and Valentini, 2012; 
Winter et al.,  2012], ortholog mapping, or integrating and combining the 
above mentioned approaches [Chen et al.,  2013, with the proposal of the 
BRIDGE algorithm; Jiang et al., 2012]. 
The  techniques  that  are  usually  employed  are:  support  vector  machine 
(SVM) [Keerthikumar et al., 2009; Li et al., 2013], neural networks, fuzzy 
algorithms, kernelized score functions [Shin et al., 2012], and other learning 
machine  procedures,  statistical  approaches  such  as  meta-analysis, 
biomedical  annotation [Feng et  al.,  2012] (such as LSI,  Latent  Semantic 
Indexing [Roy et al., 2011], PosMed or Positional PubMed [Makita et al., 
2013], GeneSniffer and SUSPECTS) [Thornblad et al., 2007; Yoshida et al., 
2009], and clustering [Bragazzi and Nicolini, 2013; Bragazzi et al., 2011; 
Jay et al., 2012]. Moreover, gene prioritizing approaches can be integrated 
with more classical, statistics-based techniques [Jiang et al., 2014].
In  the  following  chapters,  we  will  explore  selected  clinically  relevant 
examples of nanogenomics for personalized nanomedicine.
Molecular  gene  signature  of  operationally  tolerant  patients  from  kidney 
allograft  has been discovered via gene microarray and DEGs analysis. In 
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collaboration  with  Nantes  University,  France  we  used  a  previously 
described algorithm named “Leader-Gene” to study the interaction networks 
and  find  the  most  important  genes  [Bragazzi  et  al.,  2011]  taking  into 
account both interconnections and fold changes in expression, factors that 
we  named  statistical  and  biological  significance  parameters.  Operational 
tolerance was extensively studied at a cellular level using RNA interfering 
silencing technology [Braud et al., 2008; Racapé et al., 2012; Sivozhelezov 
et al., 2008], with the goal being to study and dissect the molecular basis of 
the  tolerance  which  would  enable  patients  to  avoid  taking 
immunosuppressive drugs.
As already described in literature we found that differential genes tend to 
form a highly compact and dense core network. We also found that  first-
ranked genes tend to be connected forming forward loops [Mangan et al., 
2003] and other network modules that are significantly over-represented in 
respect to randomly-generated networks [Brazhnik et al., 2002]. 
Integrated genomics–proteomics data was also the idea inspiring a research 
devoted to the identification of those genes responsible  of the malignant 
transformation of T-lymphocytes [Bragazzi et al., 2011; Braud et al.,. 2008; 
Brazhnik  et  al.,  2002;  Mangan  et  al.,  2003;  Racapé  et  al.,  2012; 
Sivozhelezov  et  al.,  2008;  Sivozhelezov  et  al.,  2010].  Some genes  were 
found  promoting  this  biological  process,  some  preserving  the  normal 
lymphocyte  functions,  and  others  being  neutral.  The  interaction  map 
appeared to be dominated by kinases and cytokines, and above all by LCK, 
playing a key role in two regulatory complexes. The interplay of genomics, 
proteomics, transcriptomics, and metabolomics is emerging as a powerful 
tool to analyze human disorders and providing the patient a personalized 
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cure [Jain,  2008;  Jain,  2009; Jain,  2010;  Nicolini  et  al.,  2012].  In  2007, 
Barabasi introduced the concept of “diseasome” in the frame of the network 
medicine [Barabasi, 2007]. 
In all of the above the goal is to investigate the medical properties of this 
supernetwork comparing the theoretical results with real electronic patient 
registers (EPR) data [Jain, 2008].   
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4.1. DNASER
DNASER, which is  an acronym staying for  DNA analySER,  is  a  newly 
conceived  microarray  scanner  and  reader  [Nicolini  and Pechkova,  2010; 
Nicolini  et  al.,  2002;  Nicolini  et  al.,  2006;  Nicolini  et  al.,  2012; 
Sivozhelezov et al., 2010; Troitsky et al., 2002].
A white light beam produced by a Xenon lamp emitting a light source of 
150  W,  accurately  filtered  and  focused,  illuminates  the  target  sample 
enabling the acquisitions of images of high sensitivity. DNASER makes use 
of a wide–band charge-coupled device (CCD) camera (ORCA II Dual Scan 
Cooled 12–14 bit B/W, Hamamatsu), a progressive scan interline designed 
to  eliminate  the  need  for  a  mechanical  shutter.  Software  routines  that 
implement the image processing algorithms for the spot analysis are written 
in C language [Sivozhelezov et al., 2010].
This special high-performance set-up combines high-resolution (an effective 
1280 × 1024 (1.3 M pixel) pixel array), low noise, high quantum efficiency, 
as well as a wide spectral response (300–700 nm) and a high dynamic range 
(full well capacity of 16,000 electrons and of 40,000 with binning). 
Microarrays  are  grids  consisting  of  built  spots  laying  equidistantly  and 
while the orientation error of the grid is negligible, its spatial position can 
significantly vary.
Furthermore,  depending  on  the  specific  arrays  used,  since  the  distance 
among  the  different  wells  is  different,  the  geometry  is  variable  and this 
should taken into account while analyzing the micro-array experiment. In 
order  to  develop  a  robust  system,  the  image  processing  algorithm  was 
designed to perform the spot analysis in a fully automated way, without any 
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additional information about the DNA micro-array geometry [Nicolini et al., 
2002; Sivozhelezov et al., 2010].
This device permits to acquire wider images, in a faster way (in a single 
shot) and of higher quality than the traditional systems, even using samples 
with very low fluorescence intensity.   
The input data to the spot analysis can be DNA micro-array images, as well 
as other kind of micro-arrays. The output data of this processing are all the 
spot features:
• Brightness features (chip spots intensities);
•  geometric  features  (spatial  distribution,  area,  circularity  and  other 
parameters) (Nicolini et al., 2002).
DNASER makes use also of two interchangeable interference filters, which 
being  situated  between  two  achromatic  doublets,  can  work  in  parallel 
illumination  conditions.  These two filters  are  different  because are tuned 
respectively on the excitation and emission frequency of the DNA micro-
array fluorescent spots. 
This geometry is used both for illumination of the sample and collection of 
the fluorescence signal. The light of desired and selected spectral properties 
is then focused onto the sample at 45 degrees of incidence. Figure 2 shows 
the main hardware blocks of the instrumentation. The illumination system, 
the optical filter system and the motorized holder blocks constitute the opto-
mechanical components.
Three  motorized  linear  translation  stages  are  used  to  fine  position  the 
sample on the focal plane (along the z axis) of the CCD camera and to select 
the appropriate portion of area to be imaged (along the x, y axis). An ad hoc 
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software  has  been  developed  in  order  to  position  the  sample  with 
micrometer precision.
The  acquired  images  can  be  analyzed  using  different  image  processing 
software,  such as  GenePix  Software.  The  image  was  acquired  above an 
intensity threshold, considered significant. The identification of the spots is 
usually realized by comparing the image with a grid, which contains every 
information  needed  (e.g.,  coordinates  and  gene  names)  to  recognize  the 
spots (Figure 2).
Figure 2: a scheme of the DNASER (left) and a picture of it (right (taken  
from [Troitsky et al., 2002] and [Sivozhelezov et al., 2010]).
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4.3. LEADER GENE ALGORITHM 
Pieces  of  information  about  gene  expression  and  regulation  in  a  given 
biological system  (such as a biochemical or biophysical reaction) or in a 
disease  are  the  main  goal  of  functional  genomics.  In  the  last  years,  the 
search  has  shifted  from  studying  a  single  gene  deregulation  to  the 
investigation of all the gene-gene interactions and networks, finally arriving 
to the concept of genomic signature [Lammers et al., 2012].
The main purposes of gene-ranking or gene prioritization [Masoudi-Nejad et 
al., 2012] are to provide robust molecular signatures of the studied events, in 
order to discover reliable, sensitive and reproducible biomarkers, as well as 
to  predict  gene  function  (GFP),  or  further  biological  targets  of  potential 
pharmaceutical interest [Xu and Wang, 2013]. 
The Leader Gene approach exploits a search-dependent statistical algorithm, 
which is based on the systematic, exhaustive and recursive search for the 
genes and their products,  on the computation of their interaction map, and 
on their ranking according to the number of all experimentally established 
interactions, as derived from publicly available Web-servers and databases, 
such  as  STRING  (Search  Tool  for  the  Retrieval  of  Interacting  Genes, 
Heidelberg, Germany) [von Mering et al., 2005]. 
The comprehensive search is usually carried out mining different databases 
and repositories containing DNA micro-arrays data, integrating the obtained 
hits. 
The  computation  of  an  interaction  map  of  the  obtained  list  of  genes  is 
computed  using the  weighted  number  of  links  (WNLs).  This  measure  is 
calculated  for  each  gene  using  the  program STRING,  and  this  value  is 
derived from the weighed sum of three types of interactions: 
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1. literature co-occurrence of the names of genes, and/or their products in 
abstracts of papers available on the Internet. The scores assigned are 
derived from benchmarked and validated scoring system based on the 
frequencies  and  distributions  of  gene/gene  products  names  in  the 
aforementioned  abstracts.  The benchmarks  themselves  are  set  from 
manual evaluation of predictions of gene and protein interactions by 
experts, and are typically below 0.5; 
2. scores derived from databases dedicated to gene networks, containing 
data on induction and expression of a particular genes by other genes 
derived from microarray experiments, or other high-throughput omics 
techniques. The score of 1 is assigned if the link is already present in 
the database, while putative links have lower values (typically in the 
range 0.6–0.8); 
3. the same range of scores is assigned to gene interactions via physically 
observed  protein-protein  interactions.  The  software  does  not 
discriminate  between  in  vivo or  in  vitro experiment  derived  data. 
Generally, the scores are close to those of interaction type 2, but links 
of this type occur much rarely than of type 2. 
The combined association scores  Sij were summed for each gene i over its 
neighbors (i,j),  giving the final weighted number of links for the gene  i. 
Further, we applied clustering methods to the weighted number of links in 
order  to  identify the group of  leader  genes.  Cluster  analysis,  also called 
segmentation analysis or taxonomy analysis, is a way to partition a set of 
objects into homogeneous and separated groups or clusters, in such a way 
that  the  profiles  of  objects  in  the  same  cluster  are  very  similar  and  the 
profiles  of  objects  in  different  clusters  are  quite  distinct.  In  particular, 
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cluster analysis can be defined as follows: 
Given a set S of n objects {x1, x2,.. ., xn}, where each object is described by 
m attributes xi=(xi1, xi2,.. ., xim), determine a classification that is most likely 
to have generated the observed objects. 
Genes belonging to the highest rank are defined as “leader genes” or “hub 
genes”  because  they  may  be  assumed  to  play  an  important  role  in  the 
analyzed processes. The “Leader Gene approach” can suggest a list of few, 
but  strong  candidate  genes  potentially  relevant  within  a  given  cellular 
process or a pathology, according to the already available experimental data. 
Moreover, the interaction map among all  the genes involved in the same 
process may be useful in interpreting the experimental and clinical results, 
and in planning new  ad hoc targeted experimentation.  Interestingly,  such 
experimentation may be simpler to be analysed than mass-scale molecular 
genomics, whose wealth of details may raise problems and complications 
[Nicolini, 2006; Nicolini, 2010]. This computational method gave promising 
results, when applied to the human T lymphocyte cell cycle, human kidney 
transplant,  oral  lichen  planus  and  periodontitis.  These  results  were  also 
integrated with a targeted experimental analysis, to draw an overall picture 
of these processes, and are reviewed in the following paragraphs. 
This  interactive,  automatic  and  user-friendly  stand-alone  tool  has  been 
written  in  house  in  Java,  Javascript,  PHP  and  HTML.  The  completely 
automated pipeline is performed via NCBI e-utilities (e-search, e-fetch, for 
further information the author is referred to the NCBI site), and other similar 
facilities. 
A pictorial scheme of this tool is given in Figure 3, while the algorithm is 
shown in Figure 4.  
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Figure  3:  screen-shot  of  the  software  GenEthics  based  on the  Leader  
Gene algorithm. 
The clustering techniques the user can choose are: Clustering K-means and 
Chinese whispers (specifically designed for graph clustering); as far as the 
number of clusters is concerned, the user can choose from heuristic number 
or provided by the user himself.  
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Figure 4: the algorithm of the GenEthics software. 
 
Moreover, it is possible also to compute different topological properties of 
the bio-graphs obtained, such as the number of nodes and edges, the mean 
connectivity,  the  graph  degree,  diameter  and  size,  the  density  and 
heterogeneity,  the  clustering  coefficient,  and  the  percentage  of  some 
particular sub-networks [Racapé et al., 2012].-  
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5. NANOPROTEOMICS 
Nanoproteomics can be defined as that broad, multidisciplinary science that 
studies protein structure and functions in an innovative way with respect to 
the  previous  methods  [Nicolini  and  Pechkova,  2010a;  Nicolini  and 
Pechkova, 2010b].
Here, the prefix “nano-”, once again, has a lot of nuances and meanings: it 
refers to the fact that nanoproteomics exploits the nanobiotechnologies, but 
also  to  the  fact  that  it  enables  the  study  of  peptides  using  very  small 
amounts of them and despite the low-consumption it offers a high sensitivity 
and specificity in the protein detection and analysis.
Throughout the years, different approaches have been developed and tested 
to  assay  the  protein  structure  and  function.  In  the  former  case,  many 
examples  can  be  quoted:  from  the  single-molecules  techniques  such  as 
atomic  force  microscopy  (AFM),  MS,  the  biomembrane  force  probes 
(BFPs), the optical and magnetic tweezers, microneedles and flow-chamber 
devices,  to  the  fluorescence-based  devices  (among  the  others,  the 
fluorescence  resonance  energy  transfer  or  FRET  techniques)  [Dufrêne, 
2009]  and  to  the  X-ray  crystallography  and  the  recent  third-generation 
synchrotrons., including the advanced Microbeam grazing-incidence small-
angle X-ray scattering (MICROGISAXS) techniques [Nicolini et al., 2014] 
(Figures 12, 13).
Nanocrystallography (Figure 5) is, of course, an important component of 
the nanoproteomics-based approaches.
 
34
Chapter 5. Nanoproteomics
Figure  5:  Experimental  lay-out  for  in  situ  μ-GISAXS  simulation  of  
protein crystallization by LB nanotemplate method. From [Pechkova et  
al., 2010a; Pechkova et al., 2010b]. 
 
As far as the function is concerned, scholars have developed and exploited 
the  nanofluidic  devices  [Okanda  and  El  Rassi,  2006;  Pasa-Tolić  et  al., 
2004].  Gold,  iron  oxide  and  silver  nanoparticles,  carbon  nanotubes, 
35
Chapter 5. Nanoproteomics
nanowires  and  porous  metal-organic-frameworks  prove  to  be  effective 
platforms  for  biomarker  discovery  [Agrawal  et  al.,  2013;  Chen  and  Li, 
2013; Dasilva et al., 2012; Jia et al., 2013]. 
MS can be  exploited  both  in  qualitative  and quantitative  ways  (Isotope-
coded affinity tags or ICAT, Isobaric labeling Tandem mass tags or TMT, 
Isobaric tags for relative and absolute quantization or iTRAQ), metal-coded 
tags  or MeCAT, N-terminal  labeling,  Stable  isotope labeling  with amino 
acids  in  cell  culture  or  SILAC,  Terminal  amine  isotopic  labeling  of 
substrates or TAILS, and Selected Reaction Monitoring or SRM) [Ong and 
Mann, 2005].
A key technology in the nanoproteomics field is represented by the protein 
microarrays,  that  constitute  the  natural  evolution  of  the  concept  of 
gene/DNA  microarrays.  Moreover,  the  protein  array  represents  a  major 
advancement in the field of proteomics and of the previous biomolecular 
tools,  such  as  the  protein  purification,  expression  and  the  protein 
engineering.
Purifying a protein is a time-consuming and difficult  task. Usually a Ni-
NTA  high  affinity  chromatography  is  needed  in  order  to  capture  the 
recombinant protein that carries a poly-histidine tag. It requires a cellular 
system (usually bacterial,  but recently also mammalian,  or fungal). Yeast 
(Saccharomyces cerevisiae) or baculovirus/insects may also be used.
However eukaryotic  expression vectors should be preferred since a) they 
produce  higher  yields  of  recombinant  protein,  b)  the  produced  protein 
remains soluble (instead, in the bacterial system it may precipitate within 
the so-called “inclusion bodies”), and c) they enable to study proteins in 
their  natural  milieu  and  environment  (since  eukaryotic  proteins  undergo 
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extensive post-translational modifications). There are many cell-free protein 
microarrays (such as the in-situ puromycin capture assay, the Protein In-Situ 
Array or PISA, the DNA Array to Protein Array or DAPA, and the nanowell 
format assay), but we chose to focus on the NAPPA approach because of its 
advantages which will be presented and described in-depth in the following 
paragraphs.
37
Chapter 5. Nanoproteomics
5.1  STRUCTURAL  NANOPROTEOMICS  AND  PROTEIN 
NANOCRYSTALLOGRAPHY
In  the  last  decades,  a  major  progress  in  the  field  of  protein  structure 
determination  was  achieved  thanks  to  advancements  in  X-ray 
crystallography  combined  with  the  third  generation  synchrotron.  This 
unique method based on a combined approach is likely to remain the most 
important structure determination method for the foreseeable future. In the 
literature there is a dearth of both structural and functional studies devoted 
to  the  investigation  of  therapeutically  and  clinically  relevant  proteins, 
because of the initial crystal production reluctance and the X-ray radiation 
induced  damage,  that  limits  the  quality  of  the  collected  diffraction  data. 
Moreover, crystallization is a highly demanding and time-consuming task, 
being a real bottle-neck in the nowadays basic research. Several efforts have 
been  made  in  order  to  understand  which  factors  and  parameters  can 
influence this process. 
Langmuir-Blodgettt (LB) nano-template crystallization method has proven 
to give prominent results in target proteins crystallization. The advantage of 
using this nanobiotechnology is the higher quality of crystals both in terms 
of X-ray diffraction and radiation stability when employing the high energy 
X-ray source and focused beans, such as the third generation synchrotrons 
and  the  micro-diffraction  beamlines.  Differences  in  protein  crystal 
nucleation, formation and growth between classical hanging-drop and LB-
facilitated  crystallization  were  been  established  by a  variety  of  methods 
including  in  situ Grazing-Incidence  Small-Angle  Scattering  (GISAXS), 
laser-micro-dissection  combined  with  nano-  and  micro-focus  beamlines, 
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Raman spectroscopy and Atomic Force Microscopy (AFM) [Pechkova et 
al., 2012]. 
Introduction of LB film affects protein stability as in the case of lysozyme, 
which turned out quite thermally stable. Previously, on the basis of a mass-
scale analysis of crystal structures, we have established a role of the aqueous 
surroundings of a protein in its thermal stability. In another previous study 
we noted that introduction of LB film affects the aqueous environment of 
the protein leading to smaller numbers of water molecules.  Recently,  we 
proved that  the introduction of thin biofilms directly affects  the aqueous 
environment of the protein. 
Different crystallization techniques have been proposed during the decades, 
like  hanging  drop  vapor  diffusion  method  and  its  variant  (sitting  drop), 
dialysis, cryo-temperature, batch, and even in space (using techniques like 
free interface diffusion or FID, counter-ion diffusion or CID). Recently, LB-
based  crystallization  technique  has  been  proposed  in  order  to  improve 
crystal growth and for this reason in this study is carried their systematic 
comparison out with in space ones and classical ones without LB.
Here,  using  both  bioinformatics  approaches,  namely  clustering  algorithm 
and protein alignment and Molecular Dynamics (MD), we show how LB-
based crystals can be compared with those obtained in space. 
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 Protein selection
We decided to focus our study selecting those proteins that are considered 
models  in  structural  crystallography  and  for  which  a  comparison  with 
microgravity-obtained structures was possible. Namely, these proteins are: 
lysozyme (EC 3.2.1.17, of Gallus gallus), thaumatin (plant sweet protein, of 
Thaumatococcus daniellii), proteinase K (EC 3.4.21.64, of  Engyodontium 
album, formerly known as  Tritirachium album) and human insulin (Homo 
sapiens). For each one protein, we downloaded all the structures present in 
the PDB database, then we iteratively refined the choice excluding proteins 
belonging  to  other  taxa or  radiation  damaged  structures,  and  finally  we 
subdivided  the  structures  using  the  crystallization  procedure  as  variable. 
Since protein selection is a crucial and key step for this study, we clarified 
the protocol and the flow-chart for each studied protein. 
Clustering algorithm and protein alignment
The  most  accurate  method  of  3D  protein  structure  alignment  algorithm 
based on the TM-align topological score was used. 
Root  mean  square  deviation  (RMSD)  for  C-α  atoms  was  used  as  the 
similarity measure for all structures. All calculations were performed using 
the web-based protein structure comparison tool ProCKSI. 
The clustering algorithm was used selecting the Ward distance, both as All-
against-all and as All-against-target options.
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Clustering software
The files for tree diagrams building were prepared according to the Newick 
format (file extension .newick), which exploits a standard that makes use of 
the correspondence between trees and nested parentheses. The trees were 
visualized using a tree editor, Dendroscope. 
Biostatistical analysis
Statistical  analysis  was  performed  by  means  of  Statpages  (Technical 
University of Denmark), Excel version 2011 14.1.3 (Microsoft Corporation 
–  Redmond,  Washington)  and  SPSS18  (IBM  Corporation,  USA; 
http://www-01.ibm.com/software/).  ANOVA-one  way  (Analysis  of 
Variance)  was  performed,  and  p-values  less  than  0.05  were  considered 
statistically significant. 
Molecular dynamics 
All proteins were solvated and neutralized adding Cl- or Na+ depending on 
the  charge  of  the  protein.  OPLS-aa  (optimized  potentials  for  liquid 
simulations all atom) force field.
For the long-range electrostatic interactions, we used Particle-Mesh Ewald 
(PME) method,  which  calculates  direct-space  interactions  within  a  finite 
distance using a modified Coulomb's Law, and in reciprocal space using a 
Fourier transform to build a "mesh" of charges, interpolated onto a grid. It is 
from this charge interpolation that long-range forces can be calculated and 
incorporated into the non bonded interactions in a simulated system. For the 
van der Waals interactions, a typical 12 Å cut-off was used. 
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As a result, lysozyme was put in boxes of 6X6X6 nm, thaumatin in boxes of 
7.4X7.4X7.4 nm and proteinase K in boxes of 7.23X7.23X7.23 nm. 
A standard equilibration procedure was used and adopted for all systems. 
We started with a conjugate gradient minimization procedure and then with 
a  two-stages  equilibration,  each  step  consisting  of  100  picoseconds 
molecular dynamics simulation. In the first step protein was frozen in space 
and only solvent molecules were equilibrated, in the second step all atoms 
were equilibrated.
The obtained configurations were used as the starting point of other 1,000 
picoseconds  NpT  (isothermal-isobaric)  simulation,  using  a  statistical 
mechanical ensemble maintaining constant temperature and pressure. 
Visualization software
Chimera  software  (Chimera  LLC,  UCSF)  and  VMD  software  (Visual 
Molecular  Dynamics,  available  on  the  World  Wide  Web  at 
www.ks.uiuc.edu/Research/vmd/) were used for visualizing MD simulations 
snapshots. 
Radius of gyration
The radius of gyration of an object describes its dimensions, calculated as 
the root mean square distance between its center of gravity and its ends. In 
analyzing  proteins,  the  radius  of  gyration  is  indicative  of  the  level  of 
compaction  in the structure,  i.e.  how folded or  unfolded the polypeptide 
chain is. The comparison was carried out on four different model proteins 
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using both biostatistical analysis, bioinformatics approaches and molecular 
dynamics (MD). 
Biostatistical analysis
We  looked  for  an  explanation  of  the  findings  obtained  from  clustering 
analysis from a quantitative and bio-statistical point of view: as can be seen 
in Fig. 3, LB insulin crystal follows the trends of microgravity crystals, that 
is to say higher resolution, lower content of water (in term of the Matthew 
coefficient),  lower  B-factor  (i.e.  thermal  noise  and  atom  displacement), 
higher number of reflections (i.e. the crystals diffract better).
ANOVA-one  way  (analysis  of  variance)  in  fact  shows  statistically 
significant difference among the groups for B factor (p-value <0.05, with 
p=0.024) and for water content (p-value <0.05, with p=0.032).  In Figures  
5,  6  and  7,  trends  comparisons  for  Resolution,  B  factor  and  solvent 
percentage among different crystallization techniques are shown, with the 
vertical  bar showing the sigma level  of the data  and the yellow line the 
average behavior of the structures. As we can see the behavior of LB-based 
crystals is comparable with the behavior of space-grown crystals and thus, 
even though clustering results are positive for lysozyme and human insulin 
and partially negative for thaumatin and proteinase K, the statistical analysis 
of some parameters (like Resolution, B factor, solvent content) showed a 
common trend shared by the two crystallization techniques.
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Figure  5:  trends  comparisons  for  resolution  among  different  
crystallization  techniques  for  all  the  four  studied  target  proteins  are  
shown, with the vertical bar showing the sigma level of the data and the  
yellow line the average behavior of the structures.
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Figure  6:  trends  comparisons  for  the  normalized  Debye-Waller  factor  
(DWF,  known  also  as  B  factor  in  the  field  of  macromolecular  
crystallography)  among  different  crystallization  techniques  for  all  the  
four studied target proteins are shown, with the vertical bar showing the  
sigma level of the data and the yellow line the average behavior of the  
structures.  
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Figure 7: trends comparisons for solvent content (in percentage) among  
different crystallization techniques for all the four studied target proteins  
are shown, with the vertical bar showing the sigma level of the data and  
the yellow line the average behavior of the structures.    
Human insulin
LB nanobiotemplate-based human insulin was first solved (PDB ID 4ihn) 
and the resolution distribution for Human Insulin structures makes evident 
that the LB insulin structure (4ihn) is the best among the 465 structures be-
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ing deposited by all  the different  crystallization methods,  existing world-
wide.  
Using ProCKSI server and our LB insulin as target structure we compared 
our LB structure with those structures already deposited in PDB database, 
taking into account similar experimental condition of crystallization. 
A summary of the investigated structures is in  Table 1. We found that the 
most similar structures to LB insulin are space-grown obtained crystals (as 
can be seen from Figures 7 and 8, and in Appendix 1), pointing to the fact 
that our LB insulin structure  was clustered together with the microgravity 
cluster.  
  
INSULIN METHOD PDB IDS
HANGING DROP 1B9E, 1GUJ, 1HTV, 1LPH, 1TYL, 1TYM, 1UZ9, 
1W8P, 1XDA, 2C8Q, 2C8R, 2CEU, 2G54, 2G56, 
2OLY, 2OLZ, 2OM0, 2OM1, 2OMG, 2OMH, 
2OMI, 2QIU, 2R34, 2R35, 2R36, 2VJZ, 2VK0, 
2W44, 2WBY, 2WC0, 2WRU, 2WRV, 2WRW, 
2WRX, 2WS0, 2WS1, 2WS4, 2WS6, 2WS7, 3BRR, 
3EXX, 3ILG, 3INC, 3IR0, 3KQ6, 3P2X, 3P33, 
3Q6E, 3ROV, 3TT8, 3UTQ, 3UTS, 3UTT, 3V1G, 
3V19, 3ZQR, 3ZS2, 3ZU1
LB 4IHN
BATCH 1QIY, 1QIZ, 1QJ0, 1ZEG, 1ZEH, 1ZNJ
SITTING DROP 3U4N
MICROGRAVITY 1BEN, 1G7A, 1G7B, 1MSO, 1OS3, 1OS4, 3E7Y, 
3E7Z, 3I3Z, 3I3Z, 3I40
Table 1: all the Human Insulin PDB structures that have been used for  
the clustering tree, divided according to their crystallization technique.
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Figure 7: inclusion/exclusion flowchart for PDB insulin structures.
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Figure 8: clustering diagram for Human insulin structures deposited on 
PDB. The clustering analysis has been performed via ProCKSI server.
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Lysozyme 
Once again,  confirming the results obtained with lysozyme structures we 
compared  all  the  Hen Egg-White  Lysozyme  (HEWL) structures  in  PDB 
database.
Our LB-obtained structures are PDB ID 2aub, 4ias, and 4iat,  which have 
been recently acquired. Using clustering algorithm we found an exceptional 
quality structure space-grown lysozyme structure (PDB ID 1iee) clustering 
with 2aub, with the RMSD of only 0.09 Å, together with other high quality 
lysozyme  crystals  among  the  structures  most  similar  to  the  LB-based 
lysozyme (as shown in  Fig. 9). The LB clusters are well reproducible, as 
well as the LB-microgravity ones.  
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Figure 9: clustering diagram for HEWL lysozyme structures deposited on  
PDB. The clustering analysis has been performed via ProCKSI server.
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Thaumatin
Even if LB structures did not cluster together with the space-grown ones, 
LB  and  space-obtained  crystal  clustered  with  each  other  (Figure  10), 
suggesting that these kinds of crystallization give more reproducible results 
that other crystallographic techniques. 
Figure  10:  clustering  diagram  for  thaumatin  structures  deposited  on  
PDB. The clustering analysis has been performed via ProCKSI server.
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Proteinase K
In this  case only space-grown crystals  result  in reproducibility of results 
(Figure 11).   
Figure 11: clustering diagram  for proteinase K structures deposited on  
PDB. The clustering analysis has been performed via ProCKSI server.
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Molecular dynamics
Figure 12 shows the RMSD and Figure 13 shows the normalized radius of 
gyration’s  behavior  of  the  analyzed  structures  at  300° K,  where  in  both 
cases strikingly differences can be seen. 
Figure 12: root mean square deviation  (RMSD) of the selected crystal  
structures simulated with molecular dynamics at 300 K.
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Figure 13: radius of gyration of the selected crystal structures simulated  
with molecular dynamics at 300 K.
In conclusion, space-grown crystals is a topic that has fostered to produce a 
huge body of research and has raised also some controversies. While some 
scholars  claim  that  in  absence  of  gravity  crystal  growth  is  better,  other 
studies  show  no  difference  between  ground-grown  and  space-grown 
crystals. 
However,  it  has  been  claimed  that  microgravity  environment  should 
minimize  “buoyant  convection  flows,  limiting  nucleation  sites,  and  
eliminating crystal sedimentation” [Ng, 2002]. 
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We found that for lysozyme and human insulin structures were absolutely 
comparable, while similar evidence was collected also for Thaumatin and 
proteinase K.
From  clustering  algorithm,  bioinformatics,  and  biostatistics,  we  can 
conclude that : 
1) bioinformatics and clustering algorithms can be applied to the study and 
modeling  of  proteins  crystallized  according  to  different  crystallization 
techniques;
2)  according  to  the  clustering  algorithm  and  statistical  analysis  of 
parameters  like  resolution,  B-factor,  solvent  content,  LB-based  and 
microgravity  proteins  are  comparable  and  different  from  proteins 
crystallized with other techniques;
All  these  findings  obtained  with  bioinformatics  and  MD  approaches,  if 
taken together  are converging and prove that LB-proteins and space-grown 
ones  are  similar  and  appear  the  best  methods  to  carry  out  protein 
crystallization .
In the second part of our structural proteomics study we used an advanced 
technique  in  order  to  get  insight  on  protein  crystallization  with  the  LB 
nanobiotemplate.
Grazing-incidence Small Angle X-ray scattering (GISAXS) is an advanced 
scattering  technique  that  can  be  used  to  unravel  these  processes  and  to 
investigate large-scale structures in thin films, including biofilms. 
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A combination of this technique with third-generation synchrotron radiation 
micro-beams (μ-GISAXS) [Pechkova et al., 2010a; Pechkova et al., 2010b] 
has been used for studying different kinds of surfaces, like surface gradients 
or confined surfaces.  The potential  for studying thin protein films by  µ-
GISAXS  during  nanotemplate-assisted  crystallization  experiments  was 
previously demonstrated in a study about the effect of temperature on long-
range order and during both  ex situ and  in situ experiments.  Ex situ data 
obtained using both Cytochrome P450scc and Lysozyme were extremely 
complex to interpret and needed to be studied in parallel with microscopy 
characterization,  using  either  the  classical  method  or  the  nanotemplate 
hanging-drop method, as well as in situ data.
Moreover,  ex situ experiments were partially limited by the discontinuous 
nature  of  the  studies  themselves  and  for  addressing  this  issue,  in  situ 
experiments were carried out, designing an  ad hoc apparatus, namely the 
flow-through  crystallization  cell,  which,  besides  the  conventional 
crystallization set-up, is  made up by two kapton windows being inserted 
into the outer cell walls (Figure 5). For obtaining a rapid and proper buffer 
exchange,  the  reservoir  was  connected  via  Teflon  tubes  to  two Harvard 
syringe  pumps.  The  main  advantage  of  in  situ experiments  was  the 
possibility of monitoring the different processes of crystal  growth in real 
time. 
The aim of this work is to shed light on the processes of nucleation and 
crystal growth starting from a LB-protein film by quantitatively analyzing 
previously acquired  in  situ µ-GISAXS experiments  with  suitable  models 
[Pechkova et al., 2010].  
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Experimental Thaumatin and Lysozyme μ-GISAXS
In  situ scattering  experiments  were  performed  at  the  ID13  microfocus 
beamline  facility  at  the  European  Synchrotron  Radiation  Facility  in 
Grenoble, France.  
A  typical  µ-GISAXS pattern is  indexed  as  function  of  the  wave-vector 
transfer  Q=(Qx,Qy,Qz) which parallel Qy and perpendicular Qz components 
scale with the in-plane 2ϑ and exit αf scattering angles. Knowing αi  is the 
grazing incidence angle, QY and QZ can be computed as follows:
QY = 2π/λ sin(2ϑ) cos(αf) 
QZ = 2π/λ [sin(αf)+ sin(αi)] while Qx is negligible in most conditions.
The specular and the so called Yoneda Peak occurs as characteristic features 
in the scattering patter.  
Specular scattering is observed for  Qx = Qy = 0,  Qz >  0, with the specular 
peak appearing when the specular condition is fulfilled (αi=αf), and while 
diffuse scattering is observed for  Qz Qy ≠  0. The so called Yoneda Peak 
αc=αf  occurs at the critical angle αc of the sample. Correlations vertical to 
the sample surface can be probed along Qz at Qy = 0.   
Data reduction
The Fit2D software package was used for data reduction. GISAXS patterns 
were analyzed with the IsGISAXS software which is dedicated to simulation 
of scattering from supported nanostructures. The scattering cross section is 
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expressed in terms of island form factor and interference function and the 
specificity of the grazing-incidence geometry is stressed, in particular in the 
evaluation  of  the  island  form  factor  in  the  distorted-wave  Born 
approximation  (DWBA).  A  full  account  of  size  and  possible  shape 
distributions is given in the decoupling approximation (DA), where sizes 
and  positions  are  not  correlated,  and  in  the  local  monodisperse 
approximation (LMA). Two types of island repartitions on the substrate can 
be implemented: disordered systems characterized by their particle-particle 
pair correlation functions, and bidimensional crystalline or paracrystalline 
systems of particles. 
Choice of parameters   
TABLE 2 . Modeling Parameters of the simulation. Value
Wavelength (nm) 0.0991 
Incident angle (deg) 0.71
Delta – Glass (index of refraction) 3.336e-6
Delta – Thaumatin (index of refraction)
Delta- Lysozyme (index refraction)
2.19e-6
Beta – Glass (absorption) 1.68e-8
Beta – Protein (absorption) ~0
LB 2 Layers thickness Thaumatin (nm)
LB 2 Layers thickness Lysozyme (nm)
7.4
6.4
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In  table  1,  the  parameters  which  have  been  used  in  our  simulation  for 
modeling the crystal growth have been reported.  
Proteins have been modeled as cylinders, LB film thickness, found with the 
best fit, was fixed at 7.4 nm for Thaumatin and at 6.4 nm for Lysozyme, 
while  the  wavelength  was  experimentally  known  (0.0991  nm).  Critical 
incident angle for Thaumatin and for Lysozyme was computed to be 0.71 
deg. The delta refraction coefficients were 3.336 ∙ 10–6 for glass, 2.19 ∙ 10–6 
for proteins. The beta absorption coefficients were about 0 for proteins, 1.68 
∙ 10–8 for glass. 
Curves  have  been  fitted  with  a  χ2 Levenberg–Marquardt  minimization 
procedure. 
Unique  combination  of  GISAXS,  synchrotron  microfocus  beam  and 
computer simulation has enabled us to follow the nucleation and growth of 
the Lysozyme and the Thaumatin crystals.  
At 100 minutes, the particle radius of Thaumatin is about 5.62 nm, while the 
LB-film layer thickness is about 2.25 nm, with height ratio of 1 nm (Figure 
14, where is shown the perpendicular cut along QZ).
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Figure 14:  Thaumatin – 100min – Modeling crystal  growth. Cylinder:  
Size = Fixed – Height = 1.7nm – Fixed LB thickness = 7.4 nm.
At 900 minutes  from the start  of the experiment,  the particle  radius  has 
increased up to 40.89 nm, while on the contrary the LB-film layer thickness 
has decreased down to 0 nm, with a decreased height ratio of 6.30·10-2 nm. 
In figure 7 the cut at Q parallel is shown at right, while at left of the same 
Figure 15 the cut at Q perpendicular  is shown.
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Figure 15: thaumatin – 900min – Modeling crystal growth. Cylinder: Size  
= 95 nm – Height = 5.6 nm – Fixed LB thickness = 7.4 nm. Blue line =  
Simulation  with  fixed  LB  thickness  =  14.8  and  3.7nm.  Perpendicular  
wave-vector  transfer  QZ (nm–1)  (left),  parallel  wave-vector  transfer  QY 
(nm–1) (right). 
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Previously,  we hypothesized  that  the  protein  appears  to  transfer  directly 
from  the  nanobiostructured  film  into  the  drop  to  directly  trigger  the 
formation of the crystal, therefore highlighting the physical interpretation of 
the  mechanism  for  nanobiotemplate-facilitated  protein  crystallization 
[Pechkova et al., 2010a; Pechkova et al., 2010b]. This working hypothesis 
however  was  only  qualitative  and  not  quantitative,  since  the  GISAXS 
spectra  were  complex  and  difficult  to  interpret.  Indeed  only  computer 
simulation  can  help  us  in  understanding the biological  processes  at  sub-
micron  and  nano-scale  level,  thus  shedding  light  on  protein 
nanocrystallography and paving the way for further research in the field. 
For Lysozyme, a comparison between with and without LB-thin film was 
indeed possible in a different way, because the acquired data were quite less 
optimal than the Thaumatin one due to a poor alignment.
The process of crystal growth previously found for Thaumatin was found 
also for Lysozyme: in Figure 16, the Gaussian fit of the Yoneda peak region 
of LB-Lysozyme monitored at start and at end of the crystallization process, 
showing the  gradual  increase  in  R (which  is  the  ratio  of  crystal  protein 
scattering volume to glass scattering volume elevated to the square). At Q 
perpendicular cut, R is 0.27 at the beginning (Figure 16, left) and gradually 
shifts to 1.13 (Figure 16, right).  
63
Chapter 5. Nanoproteomics
Figure 16: Gaussian fit  of Yoneda peak region of LB-Lysozyme at the  
start (left) and at the end (right) of the crystallization process. R is the  
ratio of crystal protein  scattering volume to glass scattering volume to the  
square.  .
Taken together the data of Lysozyme and of Thaumatin, we have proved 
that LB-thin film acts a transferring nanobiotemplate and can really enhance 
and facilitate crystallization growth, which is often difficult and demanding.
Moreover, the quantitative findings we obtained are in perfect agreement 
with the model previously hypothesized. 
The  models  here  introduced  are  based  on  the  submicron  GISAX 
experiments being previously carried out at the ID13 beamline at ESRF on 
Thaumatin and Lysozyme  and  point to an highly unstable time dependent 
growth for Lysozyme crystals contrary to what is happening for Thaumatin 
growth. In addition the lysozyme experimentation appear compatible with a 
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model  where  the  LB crystals  keep growing at  a  constant  rate  while  the 
classic crystals interrupt their growth in the same time interval.
LB-grown proteins show peculiar and unique features at the submicron size. 
LB-assisted crystal  growth was previously studied by means of AFM,  ex 
situ and in situ μ-GISAXS but obtained data were complex and difficult to 
reduce. IsGIXAS has enabled to model the crystal growth. 
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5.2. FUNCTIONAL NANOPROTEOMICS 
5.2.1. NAPPA
Ab initio/targeted bioinformatic analysis leads to the selection of few genes 
(Section 2 of Fig. 1) and these can be the proper target queries of NAPPA, a 
novel tool for studying proteins and protein–protein interactions in which 
proteins  are  produced  in  a  mammalian  environment  with  natural  post-
translational  modifications  occurring  and  just  in  time,  thus  preserving 
natural folding, stability and freshness. Moreover NAPPA avoids the need 
of  having  purified  proteins  and  instead  uses  plasmid-produced  ones. 
NAPPA slides were printed.  building upon the successful use of  in vitro 
translated  protein  in  standard  scale  applications,  we replaced  the  use  of 
purified proteins with the use of cDNAs. The proteins are translated adding 
a T7-coupled rabbit reticulocyte lysate (in vitro transcription–  translation, 
IVTT)  system  [Ramachandran  et  al.,  2004;  Ramachandran  et  al.,  2005; 
Sivozhelezov et al., 2010]. The engineering of each protein by adding a C-
terminal glutathione S-transferase (GST) tag enabled its capture to the spot 
through an anti-GST antibody, printed on the array simultaneously with the 
expression plasmid. NAPPA technology is promising, as it overcomes the 
problems like protein purification, storage, misfolding and denaturation that 
can occur during the generation of the micro-arrays  [Sivozhelezov et  al., 
2010].
Typically  a  fluorescent  molecule  is  bound  to  the  query  protein  by  the 
linking  antibody,  with  the  labeled  molecule  being  then  detected  via  a 
fluorescence  microscope,  flow  cytometer  or  some  other  fluorescence 
reading  instrument  such  as  the  DNASER [Nicolini  et  al.,  2006].  In  our 
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protocol (Figure 1) we eliminate the need for a labeling molecule that may 
alter the properties of the query protein, utilizing QCM_D nanogravimetry, 
mass spectrometry and electrochemistry in conjunction with Anodic Porous 
Allumina [Nicolini and Pechkova, 2010a; Nicolini and Pechkova, 2010b].
According to the protocol each sample is printed with 10×10 NAPPA spots 
of 300 μm diameter, spaced 350 μm center-to-center, using the chosen genes 
and corresponding expressed proteins  for the required medical  diagnosis, 
prognosis or treatment. As validation of the label-free NAPPA implemented 
in the protocol we use the following test genes with 4×4 spots: 
• Cdk2_Human Gene of 897 bp expressing 33.93 kDa protein; 
• Jun_Human Gene of 996 bp expressing 35.67 kDa protein;
• P53_Human Gene of 1182 bp expressing 43.65 kDa protein;
• CdKN1A_Human  Gene  (called  also  P21)  of  495  bp  expressing 
18,119 kDa protein.
The number of test  genes is  different  for QMC-D and QMC-F (three of 
them), APA (2 of them) and MS (all four of them; next chapter). Typically 
the first label-free measure is carried out at 22 °C for blank slide to quantify 
the initial value in order to calculate the variation at the end of each step 
(i.e.,  in QMC), and then on each blank slide NAPPA spots were printed 
[Nicolini  and LaBaer,  2010; Nicolini  and Pechkova, 2010a; Nicolini  and 
Pechkova,  2010b;  Pechkova  and  Nicolini,  2004;  Pechkova  and  Riekel, 
2011]. The  first step of NAPPA expression protocol was the blocking, at 
room temperature (22 °C) followed by a washing process. Gene expression 
and  protein  synthesis  took  place  at  30  °C  for  about  1.5  h.  Then,  the 
temperature was decreased to 15 °C for a period of 0.5 h to facilitate the 
proteins binding on the spot surface [Spera et al., 2013].
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The  last  step  was  the  washing:  the  quartzes  were  washed  at  room 
temperature (22 °C), in pure water since the frequency stabilized or in PBS 
with this step being repeated for  five times. The protocol described above 
was followed identically  for both control  and working reference  slide in 
QCM_D.
To  confirm  protein  expression  and  immobilization,  parallel  experiments 
were led earlier on several genes by  fluorescence microscopy on NAPPA 
spotted on microscope glass [Bragazzi et  al.,  2011; Ramachandran et  al., 
2004; Ramachandran et al., 2008; Spera et al., 2013]. The NAPPA function 
and  selectivity  with  respect  to  protein–protein  interactions  were  indeed 
confirmed [Ramachandran et al., 2004]. 
For  the  four  target  plasmid  DNAs  (Jun,  Cdk2,  P53  and  CdkN1A)  here 
immobilized onto the glass slide binary interactions between several well 
characterized  interacting  pairs  (including  Jun-Fos  and  P53-MDM2) were 
tested  and  confirmed.  The  target  proteins  were  expressed  with  rabbit 
reticulocyte lysate supplemented with T7 polymerase and the signals were 
detected  with  antibody to  GST and tyramide  signal  amplification  (TSA) 
reagent  (Perkin  Elmer).  To  verify  that  the  detected  proteins  were  the 
expected target proteins target protein‐specific antibodies were used, which 
detected only their relevant spots. The four genes were queried for potential 
interactions with different query proteins: Jun, Fos and MDM2. The query 
proteins were added to the IVT lysate that was spotted on the NAPPA.
The  interaction  was  detected  using  the  appropriate  protein-specific 
antibodies. 
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5.2.2. NANOCONDUCTOMETRIC QCM_D
From  sound  waves  generated  by  the  vibration  of  a  quartz  crystal 
microbalance (QCM) a sensor based on a quartz crystal coated with gold 
oscillating  at  a  specific  frequency  was  introduced  time  ago  [Bradshaw, 
2000; Höök et al., 2002; Rodahl and Kasemo, 1996a; Rodahl and Kasemo, 
1996b].  Binding  events  change  the  frequency by varying  the  amount  of 
mass linked to the surface. While  with a competitive label-free approach 
like Surface Plasmon Resonance (SPR) [Feley et al., 2008; Matarraz et al., 
2011; Wang et al., 2010] only kinetics and mass changes are detected, with 
the  QCM-based method here described in  addition  to  mass  changes  and 
kinetics can be detected also changes in viscosity on the surface; are indeed 
the protein conformational changes to appear causally related to the changes 
in viscosity.
In Fig. 17 our quartz crystal microbalance being recently developed [Adami 
et al., 2010; Spera et al., 2013] is shown to monitor both the variation in 
frequency (QCM-F) and dissipation (QCM-D). This nanogravimetric device 
exploits acoustic waves generated by oscillating piezoelectric single crystal 
quartz  plate  to  measure  the  frequency  at  which  the  amplitude  of  the 
oscillation driven by AC field will be strongly enhanced. The crystal will be 
in resonance at  this characteristic  frequency and the resonance frequency 
decreases at the increasing mass, provided it is firmly attached to the quartz 
crystal  surface.  By monitoring  the  frequency in  real  time  (QCM-F),  the 
temporal change in mass on the crystal can be investigated in a label free 
fashion.
The viscoelastic  properties  of  the  NAPPA quartzes  are  measured  by the 
dissipation factor (QCM-D) jointly developed with Elbatech srl (Marciana, 
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Italy).  Our system detects  the  dissipation  factor  of  the  quartz  crystal  by 
means of a detailed method usually known as the “half-width half-height” of 
its impedance curve [Spera et al., 2013]. Other methods are possible, such 
as measuring by fast acquisition the decay curve of the oscillation once it is 
suddenly  interrupted  [Bradshaw,  2000;  Höök  et  al.,  2002],  but  the 
impedance way has the advantage to maintain the crystal powered and to 
offer the whole picture of its oscillation mode. 
In our case the quartz is connected to an RF gain-phase detector (Analog 
Devices,  Inc.,  Norwood,  MA, USA) and is  driven by a  precision  Direct 
Digital  Synthesizer  (DDS)  (Analog  Devices,  Inc.,  Norwood,  MA,  USA) 
around its resonance frequency, thus acquiring a voltage vs. frequency curve 
which shows a typical Gaussian behavior. The curve peak is at the actual 
resonance frequency while the shape of the curve indicates how damped is 
the oscillation,  i.e.  how the viscoelastic  effects  of the surrounding layers 
affect the oscillation. In order to have a stable control of the temperature the 
experiments  need  to  be  conducted  in  a  chamber  having the  temperature 
maintained at 30 °C.
We have designed miniature  flow-cell to follow washing water directly on 
the quartz with a Milli-Q water flow of 10 μl/s. 
The scheme of the experimental set up is reported in Fig. 17 for QCM-F and 
QCM-D. The QCM-D nanogravimeter has been positioned in a temperature 
chamber  and  monitored  at  the  same  time  for  frequency  variation  and 
dissipation factor variation. 
“The nanogravimetric sample consists of 9.5 MHz, AT-cut quartz crystal of  
14  mm  blank  diameter  and  7.5  mm  electrode  diameter,  the  electrode  
material is 100 Å Cr and 1000 Å Au, and the quartz is embedded into glass-
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like structures for easy handling” [Spera et al., 2013]. The quartzes were 
produced by ICM (Oklahoma City, USA). We are presently upgrading and 
finalizing the version of the QCM_D prototype dedicated to NAPPA. The 
QCM_D instrument, besides being connected to the PC, has two analogical 
displays, one for frequency shift and the second for the D factor, in such a 
way that allows to visualize, at the same time, information on the mass and 
the visco-elasticity of the sample. It proves to be of great help to place the 
quartz  in a  controlled temperature chamber.  In this  way it  is  possible to 
perform  the  NAPPA  expression  protocol  directly  in  the  nanogravimeter 
giving a further innovation to our prototype. 
Another great advantage proves to have at least two inputs to attach at least 
two  quartzes  at  the  same  time  at  the  instrument  (as  for  QCM-R3),  one 
quartz as control and the other as working element performing also a direct 
match of different  measurements  controlled in real time.  The progress is 
thereby not only in the sample holder, but in the actual implementation of a 
novel  highly  sensitive  instrument  dedicated  to  NAPPA,  including  a  3D 
image display of the simultaneous variation in impedance,  frequency and 
time. The assembled QCM-D prototype has been optimized and validated 
with glycerol and various protein solutions [Adami et al., 2010].
The above quartz  crystal  microbalance  techniques  QCM-F and D-Factor 
QCM-D are used to investigate protein expression in NAPPA arrays when 
proteins  can  be  synthesized  directly  on  the  substrate  (in  situ)  and 
subsequently attached to the surface via capturing antibodies that bind the 
proteins by means of an antigen tag synthesized at one of their ends. The 
data  confirm  the  higher  sensitivity  of  QMC-D  also  revealing  with  the 
impedance curve CdK2, which instead cannot be detected by QCM-F.
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The  most  efficient  strategy  coupled  a  psoralen-biotin  conjugate  to  the 
expression plasmid DNA with the use of ultraviolet light,which was then 
captured  on  the  surface  by  avidin.  Finally,  QCM-F/QCM-D along  with 
Atomic Force Microscopy [Nicolini et al., 2013; Sartore et al., 2010] is a 
technique that not only validates protein expression occurring on the array 
surface, but also quantitatively measures the level and uniformity of protein 
expression,  comparing  directly  and  quite  favorably  to  fluorescent 
distribution and intensity as evaluated via DNASER on the same protein 
[Nicolini et al., 2006; Sivozhelezov et al., 2010].
 
Figure 17: the experimental set-up of QCM.
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5.2.3. APA
The APA surface can be prepared [Grasso et al., 2006; Stura et al., 2007; 
Stura et al.,  2010] by a suitable electrolytic  process designed to obtain a 
regular  distribution  of  deep  micrometric  holes. The  task  of  evaporating 
aluminum over  glass  has  been accomplished  by avoiding its  detachment 
during the anodization process, a typical problem due to the incompatibility 
of cold borosilicate glass to the vapors of aluminum. This phenomenon was 
contrasted by means of a thin layer of chromium (deposited by sputtering) 
as medium element between glass and aluminum.
The high aspect ratio (depth/width ratio) of the pores makes this material 
also  a  natural  wave  guide  for  any  fluorescent  molecule  present  on  the 
bottom of  the  pores,  avoiding  crosstalk  of  many  point‐light  sources  too 
close  as  frequently  in  fluorescent  NAPPA.  The  dielectric  properties  of 
Al2O3  makes  this  structure  optimal  for  the  realization  of  an  electrically 
anisotropic system; the electrochemical reactions occurring on the bottom of 
the well (caused by the interaction between the biological probe molecule 
and  the  test  molecule)  induce  variation  on  the  electrical  response  to 
alternating voltage signal, and they can be quantified by means of scanning 
electrodes moving on the surface of the array, placed in a proper solution. 
The  walls  of  the  pore  behave  like  insulator  decoupling  from  the 
electrochemical  events  occurring  few microns/millimeters  away from the 
measurement place. This option constitute the APA label‐free approach to 
the  analysis  of  protein  arrays,  since  no  fluorescent/marked  molecule  is 
utilized, while the alternative one still linked to APA requires a fluorescent 
molecule to spread the luminous signal through the APA wave guide. The 
potential of label‐free approaches to complement and even to improve other 
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detection technologies of proteins being expressed in NAPPA microarrays 
has never been higher.
The application of APA [Nicolini et al., 2013; Sartore et al., 2010; Stura et 
al.,  2010]  as  an  advanced  “on-chip  laboratory”  for  an  electrochemical 
detection of gene expressions is investigated with a NAPPA based on JUN 
and P53 gene sequences contained in an engineered plasmid vector.
At the same time the NAPPA printing on APA has proven:
• The ability to spot a colored fluid on the APA surface in discrete spots
• The ability to rapidly exchange that fluid with a different fluid
• The ability to repeat these manipulations as needed
•  The production  of  the  APA slides  in  a  format  compatible  also  with a 
fluorescence  reader  and  not  only  with  electrochemistry  [Nicolini  et  al., 
2013; Sartore et al., 2010; Stura et al., 2010]
•  The  structural  integrity  of  APA  slide  format  (either  alone  or  over 
aluminum)  has  been  proven  acceptable  for  “routine”  manipulation  and 
especially during fluorescence readings, mainly relying for the stand alone 
configuration also on alternative printing which exploits capillary forces. 
Last but not least the usefulness of APA substrate was shown [Nicolini et 
al., 2013; Sartore et al., 2010; Stura et al., 2010] as a candidate to isolate 
protein  expression  in  a  defined  space  followed  by  detection  of  the 
photoluminescence  signal  emitted  from the  complex  secondary  antibody 
anchored to Cy3 with a CCD microscope. The  fluorescence of these labeled 
proteins was clearly evident in circular shaped arrangements on a limited 
surface of APA where the proteins were confined in the pores. APA surface 
appears to allow a label-free analysis using electric impedance spectroscopy 
(EIS). It is known that with EIS it is possible to detect different amounts of 
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organic materials deposited even indirectly over conducting surfaces. After 
the  hybridization/expression  experiment,  using  a  scanning  electrode 
controlled by a manipulator (MPC 200 by Sutter Technologies) via a PC, 
different EIS measurements were performed in different spots on the surface 
of the array in phosphate buffered saline solution (PBS); the experimental 
setup  is  shown in  Fig.18 emphasizing  the  feasibility  of  using  APA for 
building microarrays..
Figure 18: APA as a proper biomaterial for biomolecular microarray.
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5.2.4. MASS SPECTROMETRY
In the present technique, we coupled the Matrix Assisted Laser Desorption 
Ionization  Time-of-flight  Mass  Spectrometry  (MALDI-TOF  MS)  to 
NAPPA  technology  and  bioinformatic  analysis  for  the  detection  of  the 
proteins translated from the cDNA on the surface of the array. However, the 
development  of  a  MALDI-TOF  MS-compatible  protein  microarray  is 
complex  since  existing  methods  for  forming  protein  microarrays  do  not 
transfer  readily  into  a  MALDI  target.  For  use  with  laser 
desorption/ionization  mass  spectrometry,  a  support  having  an 
electroconductive target surface was essential [Spera et al., 2011].
One of the challenges in evaluating the mass spectra obtained from NAPPA 
was the extra biological material present on the NAPPA together with the 
target proteins, such as the BSA protein. This also required interpreting the 
spectra of synthesized proteins in the context of the additional peptide chain, 
the  GST tag,  and the  anti-GST antibody.  Fortunately,  these  proteins  are 
present in all features of the array, and represent a “common background” In 
this  context,  then,  we  used  bioinformatic  tools  to  better  interpret  the 
obtained results, namely we developed a matching algorithm to identify in 
the spectra of the given expressed protein [Spera and Nicolini, 2008; Spera 
et al., 2011] those peaks corresponding to the “background peaks” (Figures  
19, 20).
The  current  NAPPA  chemistry  and  the  recent  advances  in  mass 
spectrometry [Anderson et al., 2011; Ho et al., 2002; Zhu et al., 2010] allow 
us to potentially validate this label-free technology even in clinical settings 
through the correlation with the tremendous amount  of  fluorescence data 
already acquired over the years [LaBaer and Ramachandran, 2005; Nicolini 
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and LaBaer, 2010; Ramachandran et al., 2004; Ramachandran et al., 2005; 
Ramachandran et al., 2008].
In this case, the end game is to demonstrate that we can identify proteins, in 
particular proteins that bind to the target proteins on the array. Towards this 
end we have shown that we can identify the expressed proteins, printing on 
gold slides 4 different genes (each one with 16×300 μm spots) ― first in a 
known configuration, then in an unknown configuration [Spera et al., 2011]. 
MS  analysis  was  conducted  successfully  by  searching  peptides  on  a 
database. Key to success was to do tryptic digestion and get the peptides to 
fly and to be identified. Once dried the array was placed on the MALDI 
target and analyzed. The analysis was performed with an Autoflex MALDI-
TOF mass spectrometer (Bruker Daltonics, Leipzig, Germany) operating in 
linear and reflector mode.
The resulting mass accuracy for peptides was b20 ppm. MALDI-TOF mass 
spectra were acquired with a pulsed nitrogen laser (337 nm) in positive ion 
mode, using two software programs to acquire and process mass spectra: 
FlexControl,  designed  to  configure  and  to  operate  time  of  flight  mass 
spectrometer of the Bruker's flex-series, and FlexAnalysis, designed for data 
analysis of spectra acquired with Bruker's TOF MS.
We acquired spectra for each sample (P53, JUN, CdK2, CdKN1A, A, B, C, 
D), and in order to identify the A, B, C and D samples we matched, with the 
aid of a “matching algorithm” implemented by us and described in [Spera et 
al.,  2011],  their  experimental  mass  lists  with  that  of  the known samples 
(P53,  JUN,  CdK2,  CdKN1A).  For  the  successful  protein  fingerprint 
analysis, as shown in Fig. 20 for p53, we utilized a specific tool, Biotools 
(Bruker Daltonics, Leipzig,  Germany),  that allowed an automated protein 
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identification  via  library search  with  fully  integrated  MASCOT software 
(Matrix Sciences, Ltd. www.matrixscience.com).
We can then conservatively conclude that the implemented chemistry and 
analysis  for  the  first  time  demonstrate  the  successful  use  of  mass 
spectrometry for the characterization of proteins  immobilized on Nucleic 
Acid Programmable Protein Arrays. Further development is in progress to 
bring  this  label-free  procedure  to  practice  as  an  adjunct  to  fluorescence 
NAPPA work, which has already seen significant clinical applications in the 
last  decade  [Anderson  et  al.,  2011].  The  background  generated  by  the 
reticulocytes lysate is however still  significant and need to be reduced to 
make this approach routinely applicable in the clinics. This reduction might 
be instead achieved by the use of a bacterial  cell-free expression system 
with respect to the traditional mammalian lysate [Pechkova et al.,  2010a; 
Pechkova  et  al.,  2010b],  particularly  required  by  the  highly  sensitive 
nanotechnologies  being  here  utilized.  The  application  of  bacterial 
PURExpress to NAPPA (work in progress) consists of a template double 
stranded DNA (dsDNA) containing the gene of interest fused to a SNAP tag 
and the upstream T7 promoter.  By adding the PURExpress reconstituted 
cell-free translation system, the template DNA is transcribed into mRNA, 
and then translated into a fusion protein containing the N-terminal SNAP 
tag and the C-terminal target protein. In the same spot, the SNAP tag allows 
the synthesized protein to bind to its own template DNA via the BG linkage, 
thus immobilizes the target protein. The rest of the reaction mixture can be 
washed away and the immobilized target protein is allowed to interact with 
a mixture of query proteins. After the binding reaction, the unbound proteins 
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are washed away and the target protein complex is released by cleaving the 
template DNA.
To compare  the backgrounds of NAPPA between PURExpress (bacterial 
lysate)  and  RRL  (rabbit  reticulocyte  lysate)  by  mass  spectrometry  and 
fluorescence  we  are  presently  utilizing  NEB  in  vitro system and SNAP 
fusion as an alternative to in vitro system and GST tag. Their advantages are 
higher  expression  level  and  cleaner  for  downstream  analysis,  making 
possible and really effective label free quantitative analysis at the nanoscale 
(work in progress in cooperation with the Arizona State University, ASU, 
and New England Biolabs, NEB).
Figure 19: MS MALDI standard target adapted to carry NAPPA.  From 
[Nicolini, Bragazzi and Pechkova, 2013].
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Figure  20:  MALDI  TOF  Spectra  of  NAPPA  after  protein  triptyc  
digestion, 5–20 kDa range, for optimal identification of single unknown  
genes. From [Nicolini, Bragazzi and Pechkova, 2013].
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6. MEDICAL APPLICATIONS
6.1.A REVIEW AND A STATE-OF-ART OF THE LITERATURE
In  Personalized  Nanomedicine  protein  arrays  are  primarily  employed  to 
identify  new molecular  targets  in  toxicology studies,  for  the  analysis  of 
clinical  diagnostics  to  monitor  the evolution of  a  given disease (through 
studies of drug efficacy) and for pharmacokinetics. In the context of basic 
research,  however,  protein  arrays  are  used  for  the  analysis  of  receptor– 
ligand, protein–protein and protein–DNA interactions and for the analysis of 
post-translational modifications analysis.
Label-free nanoproteomics can then be used either as discovery tool with 
thousands of genes in very few samples for screening properties [Collings 
and Vaidya, 2008; Gold et al., 2006; Madu and Lu, 2010; Umehara et al., 
2009; Wang, 2005] or for prognosis/diagnosis tool [Chikkaveeraiah et al., 
2011; Hueber and Robinson, 2006; Uetz et al., 2000] but not yet for therapy 
with single few genes in many samples for various types of cancer having 
those genes uncommon. This represents our major objective for the future. 
Indeed even if presently adapting fluorescent NAPPA to luminex appears to 
have  “per  se”  a  strong  clinical  impact  in  diagnosis,  only  label-free 
nanobiotechnologies can overcome the limitations of the fluorescence-based 
approaches for mass proteomics.  The three nanotechnological approaches 
proposed in the protocol for Personalized Nanomedicine can be used in an 
independent  and  complementary  fashion,  with  occasional  integration  of 
fluorescent labeling utilizing DNASER and APA.
Recently the high relevance of NAPPA to medicine, namely to cancer, has 
been  strikingly  proven  by  a  large  cooperation  among  leading  American 
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institutions and hospitals, and at the same time a complete body of novel 
work with label free NAPPA, has seen the press with unique experimental 
data here presented for the first time. Cancer patients indeed spontaneously 
generate autoantibodies (AAb) or tumor-derived proteins and to detect them 
the recent novel NAPPA has been successfully developed expressing 4988 
candidate  tumor  antigens  with sera from patients  with early stage breast 
cancer (IBC), and bound IgG was measured.
Using a three-phase serial screening approach NAPPA array proved capable 
to  develop  potential  biomarkers  for  the  early  detection  of  breast  cancer 
[Anderson et al.,  2011]. Label-free sensing technologies have many other 
advantages that could be exploited in new developments capable to identify 
clinically relevant proteins without the need for fluorescent tags.
Novel high-density custom NAPPA,which was recently used to detect these 
autoantibodies  in  sera  from  patients  with  early  stage  breast  cancer, 
represents  the  first  demonstration  that  the  use  of  programmable  protein 
microarrays  has  strong  medical  implication  and  high  relevance  for  the 
proteomic detection of novel disease biomarkers. While these studies were 
done using  fluorescent molecular tags, our label free approaches simplify 
signal  detection  and provide improvements  in  sensitivity,  reproducibility, 
dynamic range, and ease of use. To date, two major techniques have been 
used for the HT analysis of protein–protein interactions: yeast two-hybrid 
[Chikkaveeraiah  et  al.,  2011;  Hueber  and  Robinson,  2006]  and 
immunoprecipitation followed by mass spectrometry.
A key advantage  of the mass  spectrometry method described here is  the 
ability to identity new ligands through fingerprinting without the need to use 
antibodies. Nanogravimetry for the dynamic flow characterization warrants 
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high screening, and Anodic Porous Allumina for the high throughput at the 
highest gene and protein densities. Among the label free detection methods, 
mass spectrometry, APA and QMC_D have the unique advantage of being 
able to determine with HT not only the presence but also the identification 
of a given ligand without the introduction of extraneous molecules. Other 
needs,  not  HT,  appear  to  be  properly  addressed  by  Atomic  Force 
Microscopy for geometric static determination of the gene expressed protein 
and  its  complex  formation  with  the  query  protein.  A  new  integrated 
approach  for  medical  diagnostics  and  therapy,  termed  nanoproteomics 
[Nicolini and Pechkova, 2010], is thereby emerging also from the interplay 
between  protein  nanocrystallography  and  Nucleic  Acid  Programmable 
Protein Arrays (NAPPAs) on a previously unseen scale.
In the clinics the challenges that are still open are systemic inflammatory 
diseases such as rheumatoid arthritis and aggressive cancers with the worst 
prognosis and fast metastasis, such as pancreatic ductal adenocarcinoma.
Unfortunately nanotechniques still face several limitations to be resolved for 
a  wide  spread  application  in  biomarker  discovery,  but  currently  new 
nanoproteomics is being progressively adopted by clinical researchers due 
to increased knowledge of the pathophysiology of unresolved diseases. An 
example  actively  pursued  is  the  real-time  label-free  detection  of  protein 
interactions  in  high-throughput  format  by  NAPPA-SPRi,  where  the 
indicated  proteins  having  C-terminal  GST  E.  coli tags  were  expressed 
according to the NAPPA method, and placed on the SPRi instrument and 
the  CCD  recording  initiated.  The  proteins  were  probed  with  anti-GST 
monoclonal antibody at the time indicated and the individual sensorgrams 
were identified with protein-specific antibodies. Using SPRi when purified 
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recombinant Fos protein was used as query to probe a NAPPA array the 
binding  to  Jun  was  monitored,  and  when  purified  recombinant  protein 
MDM2 was used as query to prove the binding to p53 [Pechkova et al., 
2010].  Nanobiocrystallography  via  LB  is  a  promising  technique  for 
crystallography already proven useful for drug design and nanotubes and 
fullerene  (simulations  using  GROMACS  software)  can  represent  a 
promising approach for drug delivery [Bozdaganyan et al., 2014; Garibaldi 
et al., 2006].
Nanogenomics and nanoproteomics allow us to study and compare the huge 
amount  of  genes  and  proteins  involved  in  the  cell-cycle  progression  of 
human T lymphocytes  and in its  transformation  in  lymphoma. However, 
nanogenomics suffers many pitfalls that only functional proteomics, in the 
form of NAPPA, can overcome, probing the native in situ protein–protein 
interaction with unique sensitivity. This facilitates the identification of the 
key proteins involved in the control of cell function and enables their further 
characterization  by  structural  proteomics  at  the  atomic  level  using 
synchrotron radiation. We believe that only the interplay of new genomics, 
proteomics and other high-throughput tools as well as of nanotechnologies 
(as discussed in [Dasilva et al., 2012; Gonzalez-Gonzalez et al., 2012; Ray 
et  al.,  2011;  Walhout  et  al.,  2000;  Zhu  et  al.,  2001],  with  clinical 
correlations  and  examples)  can  be  the  successful  key  to  personalized 
medicine. It is in fact the combination of protein nanocrystallography and 
NAPPA  technologies  that  provides  the  focus  of  nanoproteomics  for 
Personalized Medicine.
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6.2.  APPLICATIONS  IN  THE  FIELD  OF  NANONEPHROLOGY 
AND KIDNEY TRANSPLANT 
In  the  broader  field  of  nanomedicine,  nanonephrology  [Jain,  2008]  is  a 
superspecialized  branch,  indicating  a  new  approach  to  the  kidney 
pathologies.  It  includes  a  comprehensive  molecular  and systems  biology 
knowledge of the kidney genes and genes products up to the atomic level, 
along  with  a  nano-imaging  based  diagnostics  in  order  to  study  cellular 
processes and events in the kidney cells [D'Agati and Mengel, 2013].
Moreover,  it  includes  all  those  novel  medical  treatments  that  utilize 
nanoparticles and to treat various kidney diseases, the creation and use of 
nanobiomaterials and devices at the molecular and atomic levels that can be 
used for the diagnosis and therapy of renal diseases. 
An  interesting  application  of  Nanonephrology  is  the  nanobiotechnoloy-
based  dialysis  filters:  human  nephron  filters  (HNFs),  blood  compatible 
nanoporous filters, ceramic filters able to reduce the time of the treatment.
Chronic kidney disease (CKD) is an important public health problem with a 
tremendous burden and social-economical implications, affecting only in the 
USA  more  than  20  million  people  and  with  an  expected  increasing 
prevalence in the near future.
It  is  a  condition  in  which  the  kidneys  damage  leads  to  a  loss  of  their 
physiological functions (filtering blood, regulating the pressure, maintaining 
acids  and  bases  homeostasis,  regulating  fluids  and  electrolytes).  Thus, 
wastes are not properly removed, their level tends to increase and this leads 
to  other complex health  problems and comorbidities,  including above all 
complications such as cardiovascular disease (CVD), hypertension, anemia, 
malnourishment  (in  particular,  protein-energy  malnutrition,  or  PEM), 
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endocrinological disorders (impaired balance of electrolytes, erythropoietin 
deficiency,  secondary  hyperparathiroidism,  hyperinsulinism,  growth 
hormone  impairment,  sexual  dysfunctions),  bone  diseases  (osteoporosis, 
osteomalacia,  osteitis  fibrosa,  osteodistrophy,  adynamic  bone  and  other 
bone  abnormalities  that  are  included  in  the  complex  clinical  syndrome 
termed as renal bone disease, or renal osteodistrophy, or CKD-mineral and 
bone  disorder),  infections  (especially,  hepatitis  C),  cancer,  and  mental 
disorders like dementia and cognitive impairment.
People with early CKD tend not to feel any kind of symptom and the only 
ways  to  detect  CKD  as  earlier  as  possible  are  through  a  blood  test  to 
estimate kidney function, and a urine test to quantitatively assess the entity 
of kidney damage. For this reason, CKD is often diagnosed when patients 
need replacement  therapy (that  is  to  say,  kidney transplantation,  chronic 
haemodialysis or peritoneal dialysis), since CKD is usually an irreversible 
and progressive disease and can  lead  to  kidney failure,  also  called  CRF 
(Chronic  Renal  Failure),  whose  last  stage  is  termed  End  Stage  Renal 
Disease (ESRD), which is fatal if it is not properly treated. Once detected, 
CKD can be managed  through medication  and lifestyle  changes  to  slow 
down the disease progression, and to prevent or delay the onset of kidney 
failure as much as possible. 
CKD is more common among women than men, more than 35% of people 
aged 20 years or older with diabetes have CKD, more than 20% of people 
aged 20 years or older with hypertension have CKD. 
The state of operational tolerance in humans has been detected sporadically 
in some renal transplanted patients who stopped immunosuppressive drugs 
and retained a good renal function, demonstrating that allograft  tolerance 
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might  exist  [for  a  review,  kidney  is  less  susceptible  to  successful 
immunosuppressive drug withdrawal than the liver [Orlando et  al.,  2009; 
Lozano et al., 2011], there is now mounting evidence showing that kidney 
transplant recipients too can become operationally tolerant [Roussey-Kesler 
et al., 2006; Newell et al., 2010; Sagoo et al., 2010]. In search of biological 
signatures of ‘‘operational tolerance’’ in humans, we previously identified a 
list  of  49  genes  which  were  able  to  discriminate  operationally  tolerant 
patients  from other cohorts  of transplant  patients  and healthy individuals 
[Brouard et al., 2007].
The gene SMILE/TMTC3 was one of the genes found to be upregulated in 
the  blood  of  operationally  tolerant  patients  and  whose  function  was 
unknown [Racape´ et al., 2011]. SMILE was found to interact with PDIA3, 
which has a crucial role in glycoprotein folding in endoplasmic reticulum 
(ER) [Zhang and Kaufman, 2008], in the loading of peptide on MHC class I 
[Santos  et  al.,  2007]  and which  is  over-expressed  during  ER stress.  We 
showed that siRNA-mediated SMILE knock-down in HeLa cells induces a 
decrease in several types of transcripts involved in protein catabolism and 
proteolysis,  particularly  immunoproteasome  subunits,  suggesting  that 
SMILE exerts its function via the proteasome pathway [Racapé et al., 2011]. 
This  was  confirmed  by  the  facts  that  SMILE  down-regulation  and/or 
treatment  with  proteasome  inhibitor  (Bortezomib)  induced  dramatic  ER 
enlargement and features of cellular injury and that Bortezomib inhibition of 
long-term  cellular  growth  was  strongly  enhanced  in  SMILE  siRNA-
transfected cells.  SMILE silencing was found to directly increase XBP-1 
transcript  expression  after  6h  of  Bortezomib  treatment,  while  DNA 
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microarray  analysis  revealed  that  SMILE down-regulation  in  HeLa  cells 
affects secretory pathways, such as vesicle-mediated transport.
Earlier, we outlined a microarray-based identification of key leader genes 
found respectively in blood from kidney transplanted patients with chronic 
rejection  or  operational  tolerance  by  utilizing  a  non-statistical 
bioinformatics approach based on the identification of ‘‘key genes’’ either 
as  those  mostly  changing  their  expression,  or  having  the  strongest 
interconnections [Sivozhelezov et al., 2008].
An  informative  picture  emerges  on  the  genes  controlling  the  human 
transplant  from  the  detailed  comparison  of  these  findings  with  the 
traditional statistical significance analysis of microarrays (SAM) and with 
the clinical study [Braud et al., 2008]. Some of these genes, such as BANK-
1,  a  modulator  of  B-cell  hyperactivation,  have  been  confirmed  through 
further studies using different techniques [Pallier et al., 2010]. In parallel, in 
another study, in a rodent model of kidney allograft, DNA microarrays were 
used to compare gene patterns in the kidney transplant from anti-donor anti-
class II tolerated or untreated syngeneic rat in the Lewis 1W and Lewis 1A 
rat strain combinations [Jovanovic et al., 2010]. Statistical and nonstatistical 
analysis combined with ab initio analysis, using the leader gene approach 
[Bragazzi et al., 2011] suggested that tolerance and rejection outcomes may 
be in large part correlated to the low expression variations of some genes, 
which can form a core gene network around specific genes, such as Rac1, 
NFKB1, RelA, AKT1, IKBKB, BCL2, BCLX, and CHUK. Through this 
model, we showed that AKT1 gene, WNT pathway and NO synthesis were 
strictly connected to each other, with AKT1 gene being the center of this 
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complex network of interactions in kidney tolerance and rejection processes 
[Jovanovic et al., 2010].
The  aim  of  the  present  study  was  to  define  networks  of  genes  either 
modified by SMILE knock-down compared to control knockdown cells or 
phorbol  12-myristate  13-acetate  (PMA)-activated  cells  compared  to  non-
activated cells. Then, we compared these two networks with those found in 
our  microarray  studies  in  human  [Sivozhelezov  et  al.,  2008]  and  rat 
[Jovanovic et al., 2010]. Gene expression microarray data representing three 
independent  experiments  from HeLa cells  transfected 24 h with negative 
control or SMILE siRNA, or activated or not with 20mM PMA during 6 h 
as  previously  described  [Racapé  et  al.,  2011]  were  submitted  for  our 
analysis.  
For each analysis, we arbitrarily fixed the FDR less than 0.5%. LOWESS 
normalization  was  applied,  we  made  a  first  visual  inspection  using  the 
Volcano Plot and its variants. Interaction networks from the genes involved 
in SMILE knockdown selected by SAM analysis (or alternatively Fisher Z-
score) resulted in large intractable networks. It is well-known that different 
statistical analysis can yield different results [Kim et al., 2006] and a need 
for combining statistical and biological significance is emerging [Draghici 
et al., 2007]. 
We performed nonstatistical analysis on the different conditions of culture 
based mostly on fold-changes [Racapé et al., 2011]. The columns containing 
d-scores and fold-changes were thus multiplied to select both statistically 
and biologically significant genes. We considered genes with both statistical 
and  biological  significant changes in expression: we performed a scatter-
plot with the number of genes versus SAM d-score and log of fold-change 
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and  we  picked  those  genes  which  resulted  in  a  significant  separation, 
selecting them for further bioinformatics analysis.
 
This approach was used to select genes included in the networks displayed 
in Figures 31, 32, and the Clusters of Orthologous Groups (COG) mode of 
STRING was used to extend these networks with family-wide and cross-
species analogs. 
Figure 21: network connecting genes up- or down-regulated by SMILE  
knock-down,  by  microarray  data  for  HeLa cells.  From [Racapé et  al.,  
2013].
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Figure 68: Semi-theoretical network of SMILE silencing.
Figure 22: semi-theoretical network of SMILE silencing.
 
Networks  have  been  proved  a  very  useful  tool  for  understanding  cell 
functions  [Barabasi  and  Oltvai,  2004]  and  in  the  frame  of  the  systems 
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biology they have been widely exploited for characterizing different cellular 
processes, among which also kidney allograft [see for a review, Perkins et 
al.,  2011].  As far as we know, this  is  the first  time that  topological  and 
mathematical  analysis  have  been  used  to  compare  the  changes  of  two 
biological networks after a gene has been knocked-down.
Genes selected with the SAM analysis form no visible physical interaction 
networks after SMILE silencing (Fig. 21). Therefore,  we formed a semi-
theoretical  interaction  network  starting  from  the  known  interaction  of 
SMILE with PDIA3 and added their neighbors based on family-wide and 
cross-species analogs (COG mode of STRING). The resulting map is shown 
in  Figure  22.  Genes  significantly  up-regulated  are  shown in  red,  down-
regulated  in  blue,  not  changing their  expression in  green.  Magenta  lines 
denote physically observed interactions between the proteins encoded by the 
respective genes, cyan lines neighborhood in known regulatory or metabolic 
pathways.  Using  this  method,  we  confirmed  that  indirect  neighbors  of 
TMTC3 are related to ER functioning and stress response genes (CANR, 
CALX, PDIA4, PDIA2, and ERP27) due to TMTC3 interaction with PDIA3 
[Racapé et al., 2011].   
In contrast to SMILE silencing, gene highlighted from the SAM analysis 
resulted in a well-defined network following PMA activation. This is likely 
due to extensive studies on PMA activation,  leading to a more extended 
knowledge  of  genes  involved  in  this  activation  than  those  involved  in 
SMILE  knock-down.  The  two  networks,  semi-theoretical  for  SMILE 
silencing and expression-derived for PMA activation, were compared to the 
‘‘pro-tolerance’’ and ‘‘pro-rejection’’ networks inferred from our previous 
studies in blood from patients with a kidney transplant [Braud et al., 2008; 
92
Chapter 6. Medical applications
Sivozhelezov et al., 2008]. SMILE gene (TMTC3) is linked via PDIA3 to 
the  network  previously  identified  in  the  blood  from human  transplanted 
kidney recipients with a profile of chronic rejection (referred above as the 
pro-rejection network): namely STAT3, TNFRSF1A, IL2RB, LCK, VAV1, 
HNRPU, and their neighbors, as described in more details by Sivozhelezov 
and collaborators [Sivozhelezov et al., 2008]. SMILE gene relation to the 
network identified in the blood from human transplanted kidney recipients 
with a profile of operational tolerance (referred above as the pro-tolerance 
network) is less direct, although one gene, IFNg is linked to SMILE again 
via  the  PDIA3 gene.  There  are  five  overlapping  genes  between  SMILE 
knock-down network and the pro-tolerance and pro-rejection networks (four 
genes pro-tolerance: TP53, ATF2, JUN, and MAPK14 and one gene pro-
rejection:  HTATIP).  We  found  that  those  five  genes  form  their  own 
network. For PMA activation and the human kidney transplantation,, there 
is  a  sub-network  of  PMA activation  most  tightly  connected  to  the  pro-
tolerance network, namely ERBB2, CD44, and IL4R. 
There is  the same situation  for  the subnetwork formed by genes RELA, 
NFKB1, and NFKBIA in comparison with the pro-rejection network.
Before  performing  our  topological  analysis,  we  verified  the  scale-free 
behavior of our networks, since this feature has emerged as a peculiar and 
distinguishing characteristic of biological networks [Barabasi et al., 2001].
From  the  ‘‘Density,’’  the  ‘‘Mean  connectivity’’  and  the  ‘‘Clustering 
coefficient’’ rows of Table 3, it appears that SMILE networks are denser 
and more clustered than PMA networks, each SMILE node having more 
neighbors than PMA. In contrast, PMA networks are more heterogeneous 
than SMILE networks. The centrality (tendency to form star-like rather than 
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mesh-like topology) is small for all the networks (maximum is 1), which is 
typical of biological networks that rarely have a single superhub. 
Finally, size of the network  is higher for PMA networks. Other parameters 
(like  diameter  and  degree)  show  little  statistical  variance  or  show  an 
ambiguous trend (namely, degree is higher for PMA in the case of tolerance 
network, while being lower for PMA in the case of rejection).
Frequency distributions of node connectivity for rejection network SMILE 
knock-down versus rejection network PMA activation showing statistically 
significant difference are also analyzed. Hub genes occur more frequently in 
rejection  network SMILE  knock-down  than  in  rejection  network PMA 
activation. Instead, frequencies for tolerance network SMILE knock-down 
versus tolerance network PMA activation show no statistically significant 
difference. We conclude that SMILE knock-down more significantly affects 
the  kidney  transplant  rejection  network  than  PMA  activation,  while  the 
tolerance network is affected to the same extent by SMILE knock-down and 
PMA activation (Table 3). 
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Parameters, samples Tolerance 
SMILE
Tolerance 
PMA
Rejection 
SMILE
Rejection 
PMA
Rat 
SMILE
Rat 
PMA
Nodes
Density
Heterogeneity
Clustering coefficient
Diameter
Centrality index
Number of neighbors
Size
Mean connectivity
Degree
FFL subgraphs
79
0.06
0.83
0.3
8
0.17
4.86
2.5
4.7
11.27
20.00%
92
0.53
0.93
0.26
8
0.16
4.85
2.65
4.76
13.36
19.50%
78
0.64
0.69
0.3
8
0.12
4.95
2.54
4.99
11.81
17.00%
83
0.47
0.76
0.25
9
0.14
3.83
3.12
3.75
9.93
16.30%
52
0.87
0.64
0.4
6
0.17
4.46
2.24
4.45
10.31
18.20%
61
0.05
0.69
0.27
9
0.14
3.02
3.19
2.98
7.94
13.7%
Table  3:  topology Parameters  of  SMILE-silencing and PMA-activation  
Networks.
As far  as  the  local  topology  is  concerned,  we  studied  the  small  motifs 
composing  the  subgraphs  of  the  network—using  a  well  established 
approach, comparing them against motifs in random networks and selecting 
only those motifs for which Z-score was higher than 2, whose P-value was 
lower than 0.05 and whose frequency was higher than five times. Our study 
showed that FFLs motifs [Mangan and Alon, 2003] are the core motifs of 
our networks and they are abundant in SMILE networks, suggesting that 
SMILE calls for more fine-tuned regulation. For the rat kidney transplant 
study, too few genes notably change expression to analyze pro-rejection or 
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pro-tolerance  network  separately.  Besides,  the  setup  of  the  microarray 
analysis (TOL/SYN and TOL/REJ) would render such analysis of separate 
networks  biased.  Therefore,  we merged  the  tolerance  and rejection  gene 
lists.
There  is  a  sub-network of  rat  kidney transplant  related  genes  interacting 
strongly with the SMILE network modulation (Fig. 8a, underlined in dotted 
line). These include RelA, CHUK, NFKB-1, NFKB-1A, and AKT1, having 
a significantly high number of links with SMILE sub-network. The same 
observation  is  even  more  pronounced  for  PMA activation.  Three  of  the 
genes mentioned above (NFKB-1, NFKB-IA, and RelA) even constitute an 
overlap between the rat transplant network and the PMA activation network. 
Topological analysis of joint SMILE knock-down and PMA activation with 
tolerance  and  rejection  networks  from  the  rat  data  from  Table  3,  also 
allowed to conclude that SMILE networks are topologically quite different 
than PMA activation networks. SMILE networks are denser, more clustered 
and  connected,  while  being  also  more  distributed.  In  contrast,  PMA 
networks are less dense and more localized around specific genes.
Node connectivity also shows significant difference as for the human data. 
Comparison  graphs  for  average  connectivities  and  clustering  coefficient 
follow the same pattern.
Considering  that  the  rat  networks  are  largely  dominated  by  prorejection 
genes [Jovanovic et al., 2010], this leads to the same conclusion that SMILE 
knock-down  more  significantly  affects  the  kidney  transplant  rejection 
network than PMA activation. Again from local topology analysis, we can 
see that SMILE network contains more FFL motifs than PMA network and 
this difference is even more strikingly true for rat compared to humans. In 
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this study, a microarray study of SMILE knock-down and PMA activation 
in HeLa cells was compared to our earlier analysis based on microarray data 
of kidney allograft tolerance and rejection in humans and in a rat model of 
heart  allograft  transplantation  to  determine  possible  new genes  and gene 
networks  involved  in  kidney  transplantation.  Based  on  bioinformatics 
analysis, we showed that at the intersection of the SMILE silencing gene 
network  and earlier  identified  microarray-based pro-rejection  versus  pro-
tolerance gene networks, five expression leader genes appear that form their 
own sub-network. These genes encode one transcription regulator, namely 
the kinase MAPK14, three transcription factors (JUN, ATF2, and TP53), 
and a histone acetyltransferase (HTATIP). This network has been expanded 
via STRING to its nearest neighbors.
Also  interesting  are  the  two  immediate  neighbors  of  this  subnetwork, 
Nephrin  and  Arrestin  b2.  Nephrin  is  a  member  of  the  immunoglobulin 
family of cell adhesion molecules that function in the glomerular filtration 
barrier in the kidney, being the structural component of the glomerular slit 
diaphragm [Ruotsalainen  et  al.,  1999].  Arrestin  b2  is  known  to  have  a 
significantly reduced expression in monocytes during kidney graft rejection 
as it has been recently demonstrated in human [Zakrzewicz et al.,  2011]. 
Nephrin  fosters  activation  of  stress-activated  protein  kinase  38  and JUN 
which acts in complex with FOS [Huber et al., 2001]. In competition with 
the  binding  of  Nephrin  to  the  podocin,  Arrestin  b2  mediates  Nephrin 
endocythosis and therefore its functioning reduction [Quack et al., 2006]. 
Note that the Arrestin b2 activation is via MAP kinase and down-regulates 
the  TGF-b signaling  pathway  [Shenoy  and  Lefkovitz,  2011].  But  most 
importantly,  the network includes the protein XBP-1 already reported by 
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Racape´  et  al.  [2011]  to  be  up-regulated  in  response  to  SMILE  down-
regulation,  reinforcing  these  previous  findings.  FOS  together  with  JUN 
forms a functional heterodimer with XBP-1 [Ono et al., 1991].
The comparison between the PMA activation network and the pro-tolerance 
network  revealed  that  visually,  the  pro-tolerance  network  appears  to  be 
more tightly connected with the PMA activation network than the SMILE 
knock-down network,  suggesting  that  tolerance  may be  associated  to  an 
activation profile. This will have, however, to be proven numerically,  for 
example, by modifying our Leader Gene software [Bragazzi et al., 2011] to 
assign scores to networks and not to individual genes.
The other finding is that SMILE knock-down networks, irrespective of the 
context,  show  topological  features  strikingly  different  from  the  PMA 
activation  networks.  Indeed,  analysis  of  the  topological  parameters  of 
SMILE knock-down and PMA activation with transplantation networks in 
human shows increased density and clustering coefficient (that measures the 
degree  to  which  nodes  in  a  graph tend to  cluster  together,  for  example, 
average  number  of  links  between  each  gene’s  neighbors)  of  SMILE 
networks,  meaning  that  SMILE networks  are  better  connected  and more 
clustered  than  PMA  networks.  Denser  networks  should  be  expected  for 
SMILE  because  SMILE  is  a  single  gene  while  PMA  activation  may 
simultaneously activate or suppress many genes possibly unlinked to each 
other.  In  contrast,  heterogeneity  of  PMA networks  compared  to  SMILE 
networks suggests that there is a larger fraction of higher connected (hub) 
genes in PMA than in SMILE networks. In other words, SMILE knock-
down leads to more evenly distributed effects on tolerance/rejection gene 
networks  while  PMA  activation  focuses  on  fewer  but  more  highly 
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connected  genes.  Finally,  PMA  networks  display  a  bigger  size  of  the 
networks (higher number of links). Larger number of links, however, does 
not mean better  connection because links may be members of (partially) 
isolated subnetworks.
Another interesting observation is that SMILE networks contain more FFL 
motifs  than  PMA which  means  a  more  sophisticated  genetic  regulation. 
Interestingly,  genes were found to be common between the two analyzed 
network combinations, SMILE knockdown network rat transplant network 
and PMA activation network rat transplant network (NFKB-1, NFKB-IA, 
and RelA). This allows concluding that common molecular mechanisms are 
involved in all three phenomena or that they are linked together through the 
same network. Besides, these results confirm our earlier  finding on AKT1 
gene in  rat  kidney transplant  tolerance  [Jovanovic et  al.,  2010],  and this 
could be better investigated in further bioinformatics studies.
Subsequently, we validated the list of found genes, namely HTATIP/KAT5, 
C-JUN, TP53, ATF2, MAPK14, ARRB2, XBP1, and NPHS1. 
We  accessed  Gene  Expression  Omnibus  (GEO),  a  public  repository  of 
micro-array  experiments,  looking  for  the  expression  profiles  of  the 
previously identified Leader Genes. 
In  case  of  different  existing  experiments  studying  the  expression  of  the 
chosen gene, the data were normalized and then pooled together. Student's t-
test for independent samples, Analysis of Variance (ANOVA)-one way and 
Pearson's correlation between gene expression in kidney and in peripheral 
blood  were  calculated  with  SPSS  software  V21.0.0  package  (IBM)  and 
using R environment. p-values were computed with SPSS, and values equal 
or less than 0.05 were considered statistically significant.
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We found that 5 out of 8 genes (62.5%) are able to distinguish between 
rejection  and  tolerance  to  kidney  transplantation,  being  differentially 
expressed between the two groups of patients in a statistically significant 
way.  Some  of  these  genes  have  been  rarely  described  as  predictors  of 
clinical outcomes to renal graft in the literature.
Pooled  Gene expression  profiles  analysis  revealed  that  HTATIP/KAT is 
able  to  distinguish  between  rejection  and  tolerance  outcome,  being 
differentially expressed between the two groups of patients with a p-value 
<0.001,  both  in  kidney  and  in  peripheral  blood.  Similar  results  were 
obtained with TP53 (p-value <0.001), C-JUN (p-value <0.001 in blood, p-
value <0.05 in kidney). ARRB2 yielded a statistically significant result only 
in kidney (p-value <0.05), such as ATF2 (p-value <0.05) (Figures 22 and 
23). 
On the contrary, MAPK14, XBP1 and NPHS1 expression profiles did not 
differ in a statistically significant way.
The lack of statistical significance for these genes may due to the limited 
existing  number  of  micro-array  experiments.  Further  experiments  are 
needed to confirm and replicate our findings.
Correlation between expression profiles in peripheral blood and in kidney 
was also studied, using Pearson's correlation. Only ATF2 tolerance profile 
in kidney and in blood yielded statistically significant results (r=-0.68, p-
value <0.001) (Figure 25).
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Figure  23:  pro-rejection  and  pro-tolerance  gene  expression  in  kidney  
tissue. p-value <0.001.
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Figure 24: pro-rejection and pro-tolerance gene expression in blood. p-
value <0.001.
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Figure 25: Pearson scatterplot showing correlation between ATF2 gene  
expression in blood and in kidney tissue.
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6.3. APPLICATIONS IN THE FIELD OF ORAL DISEASES
Oral  Lichen Planus (OLP),  first  identified  by Doctor  Erasmus Wilson in 
1869, is a chronic inflammatory oral mucosal disease affecting about 0.5–
2% of the world population, more often females, with a mean age-of-onset 
usually in the fourth decade [Anuradha et al.,  2008]. The histopathologic 
features  of  OLP  are  hydropic  degeneration  of  the  basal  cell  layer, 
hyperkeratosis,  acanthosis, irregular ridges and band-like infiltration of T 
lymphocytes mainly in the lamina propria. Although the aetiology of OLP 
is still unknown, it has been widely accepted that immunological aberrances 
are very critical  among the multiple aetiological factors. Previous studies 
have suggested that it represents a cell-mediated immunologic response to 
an  induced  antigenic  change  in  the  oral  mucosa  [Ismail  et  al.,  2007; 
Mollaoglu, 2000; Sugerman and Savage, 2002]. The inflammatory response 
in OLP is characterized by the accumulation and expansion of T helper (Th) 
lymphocytes.
Clinical features and accompanying symptoms of OLP lesions range from 
asymptomatic  reticular  white  lesions  in  atrophic  mucosa  to  erosive-
ulcerative  areas  accompanied  with pain  and discomfort.  The histological 
lesion is characterized by a sub-epithelial inflammatory infiltrate, composed 
of different mononuclear cells, dominated by T lymphocytes, and limited to 
the  basal  keratinocyte  layer  [Epstein  et  al.,  2003]. OLP  lesions  are 
characterized by a higher degree of cell turnover than healthy tissue [Scully 
and  el-Kom,  1985]. In  fact,  the  proliferation,  the  maturation  and  the 
apoptosis of basal keratinocytes require a fine regulation at a genomic level 
[Gandarillas,  2000;  Hirota  et  al.,  2002]. Moreover,  the  World  Health 
Organization  (WHO)  defined  OLP as  a  pre-malignant  condition  making 
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‘‘oral mucosa more sensitive to exogenous carcinogens and thus to develop 
oral  carcinoma’’  [Pindborg  et  al.,  1997]. However,  the  molecular 
mechanisms determining the possible development of cancer in OLP lesions 
are not well understood yet [Lodi et al., 2005a].
From these observations,  OLP may be seen as a complex multi-factorial 
disease  [Chiappelli  et  al.,  2011;  Hirschhorn,  2005;  Lodi  et  al.,  2005b; 
Orlando et al., 2013; Tabor et al., 2002].
Cluster  analysis  of the WNL identified 5 genes belonging to the highest 
cluster, i.e., the leader genes: JUN, EGFR, FOS, IL2, ITGB4. The analysis 
of variance (ANOVA) revealed a statistically significant difference in the 
WNL.  In  particular, the  post  hoc  test  revealed  that  leader  genes  had  a 
significantly  higher  WNL  when  compared  to  class  B  genes  (p-value  < 
0.001), and that class B genes differed significantly from other classes (p-
value  <  0.001 versus class C). The established or putative role of leader 
genes in OLP is summarized in Table 3. 
Table 3– leader genes (JUN, FOS, EGFR, IL2, ITGBA2) and their molecular  
functions (modified from Wikipedia and NCBI annotation).
JUN The locus 1p32-p31, whose  translocations and mutations cause several human malignancies, 
encodes an oncoprotein which, interacting directly with specific DNA sequences, plays a crucial 
role in gene expression.  
EGFR This gene encodes a transmembrane glycoprotein that belongs to the protein kinase 
superfamily. It binds to epidermal growth factor (EGF), thus leading to cell proliferation. 
FOS This gene encodes a leucine zipper protein that interacting with JUN forms the transcription 
factor complex Activator Protein type 1 (AP-1), implicated in cell proliferation, differentiation 
transformation, and apoptosis.
IL2 It encodes a cytokine that regulates the proliferation of T and B lymphocytes. 
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ITGB4 It encodes a protein that mediates cell-matrix or cell-cell interactions, thus fine tuning cell 
growth. Integrin beta 4 subunit is a receptor for the laminins and its mutation may cause invasive 
carcinoma.
Figure 26 hows up-regulated and down-regulated genes, with data obtained 
by means of data-mining. Interestingly all leader genes but EGFR were up-
regulated, while EGFR appeared neutral in respect to OLP pathogenesis. 
Figure  26:  up-  and down-regulated  genes  involved  in  pathogenesis  of  
OLP. In black: genes for which there are no or little information about  
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expression; in yellow: neutral genes in OLP disease; in red: up-regulated  
genes in OLP disease; in blue: down-regulated genes in OLP disease..
Topological analysis is summarized in Table 4. Interestingly all leader genes 
were widely distributed in the network (in term of topological parameters 
such as  stress,  eccentricity  and  radiality)  and  showed  higher  topological 
coefficients at the topological analysis. 
 
OLP network parameter Value
Clustering coefficient
Network centralization
Average number of neighbors
Network density
Shortest paths (in percentage)
Average path in length
FFLa
0.33
0.07
3.22
0.02
52
4.66
17.83
a Feed-forward loops. 
Table 4: global topological analysis for OLP network.
The bibliographic research revealed that among the 5 genes identified as 
leader  genes,  only 3 were specifically  associated with  OLP.  This  search 
confirmed that every gene identified as a leader gene can be supposed to 
play a major role in OLP at a molecular level. The analysis of the interaction 
map allowed the identification of different groups of genes corresponding to 
the  typical  aspects  of  OLP  lesion:  changes  of  the  epithelial  basement, 
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regulation  of  cell  cycle  regulation  and  interleukine/chemokine  signalling 
(see  Figure 27)  [Giacomelli  et  al.,  2009; Lodi  et  al.,  2005a;  Lodi et  al., 
2005b; Oluwadara et  al.,  2009]. Interestingly,  there is at least  one leader 
gene for each area.  
Figure  27:  ontological  analysis  of  OLP  network  showing  the  most  
important  pathways  over-represented  in  the  graph  versus  whole  set  
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annotation, carried out with BinGO software (p-value < 0.01, Benjamini-
Hochberg correction, hypergeometric clustering).
Epithelial  basement  membrane changes are common in OLP and include 
cellular  damage  as  well  as  the  degeneration  of  the  basal  keratinocyte 
anchoring elements, which may result in a weakened epithelial-connective 
tissue interface and histological cleft formation (the so-called Max-Joseph 
space) [Ixchimura et al., 2006; Karatsaidis et al., 2003; Zhou et al., 2001].
Noteworthy, it was suggested that dysregulation in integrin pathways and 
inhibition  of  the  TGFB1/Smad  pathway  could  play  a  major  role  in  the 
pathogenesis of OLP [Giannelli et al., 2006].
The b4 integrin encoded by the gene ITGB4 has different functions, ranging 
from epithelial cell adhesion (by interacting with the basement membrane 
component laminin) to cell  motility (interacting with F-actin) and also to 
immunity regulation.  Reflecting this  wide array of functions,  ITGB4 has 
been involved in a variety of oral diseases (being a potential biomarker of 
the  Warthin’s  tumour  of  the  parotid  gland,  the  tongue  squamous  cell 
carcinoma, the ameloblastoma and other oral cavity tumours, and playing as 
well  a  role  in  the  Sjogren’s  syndrome disease  and inmost  pre-malignant 
lesions,  from  oral  leukoplakia  to  oral  pemphigoid).  Moreover,  ITGB4 
expression may reflect  the response to  a dental  implant,  determining the 
success of it together with osseointegration, a well-known parameter of the 
clinical  outcome [An et al.,  2012; Andreadis  et  al.,  2005; Hamidi  et  al., 
2000; Jones et al., 1995; Kurokawa et al., 2008; Modolo et al., 2004; Sami 
et al., 2002; Velozo et al., 2009].
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EGFR too plays a key role in OLP even if its precise function is still not 
understood [Ebrahimi et al., 2008; Kumagai et al., 2010; Martin-Ezquerra et 
al., 2010]. 
EGFR has been linked to other many oral pathologies and has been found to 
have a role in oral infections and to be as well a good biomarker for both the 
diagnosis and the prognosis of oropharyngeal and oral cavity squamous cell 
carcinomas, salivary gland cancer and other oral tumours. EGFR may play a 
key role in the malignant transformation of oral pre-malignant lesions and 
the contradictory experimental findings about its expression and regulation 
in  OLP  may  reflect  different  clusters  of  OLP  in  term  of  prognosis, 
considering  that  a  fraction  of  OLP  lesion  transforms  into  a  cancer 
[Chandarana et al., 2012; Ettl et al., 2012a; Ettl et al., 2012b; Monteiro et 
al., 2012; Wali et al., 2012; Xia et al. 1999; Zhu et al., 2012]. Some scholars 
have  proposed EGFR-targeted  therapeutics  as  an  emerging  treatment  for 
oral tumours [Wali et al., 2012], while other authors have suggested to use 
anti-  EGFR  monoclonal  antibodies  for  monitoring  oral  cancers  in  vivo 
[Yang et al., 2011].
FOS and JUN control cell cycle regulation but their role in OLP is still very 
little  known.  Also  these  genes  have  been  related  to  a  variety  of  oral 
disorders, from oral infections to oral cancers, and interestingly they may 
play an important  role  in  the transition  from pre-malignant  to  malignant 
lesions [Gutierrez-Venegas et al., 2008; Mishra et al., 2010; Sachdev et al., 
2008;  Soejima et al., 2007; Turatti et al., 2005].
The third  area  in  the  interaction  map  is  represented  by interleukine  and 
chemokine signalling and T lymphocytes/macrophages infiltration. There is 
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a large evidence on a role for immune misregulation, specifically involving 
the cellular immune system [Simark-Mattsson et al., 1999].
IL2 has been found to play a major role in oral cancers, thus becoming an 
important drug target [Cheriyan et al., 2011; Covani et al., 2008; Khan et al., 
2003]. It  has  been  also  linked  with  oral  infections,  periodontitis,  oral 
autoimmune diseases and other pathologies [Gaffen and Liu, 2004; Reichert 
et al., 2009].
Noteworthy,  at  present  no  direct  link  at  a  genomic  level  is  identified 
between this area and the basal membrane alteration and cell cycle control 
areas. 
Our  topological  analysis  showed that  our  network  exhibits  a  power  law 
behaviour in agreement with the Scale-free theory of bionetworks [Barabasi 
et al., 2001; Shimbel, 1953; Stelzl et al., 2005] and has more FFL (feed-
forward loops) than one would expect to find in a random graph [Mangan 
and Alon, 2003]. The topological properties of leader genes and their role in 
controlling each pathway emerged from onthological analysis confirm our 
results   and  the  linear  regression  shows  that  OLP-related  genes  have  a 
higher  disease-related  connectivity  than  a  general  global  connectivity 
(Figure 28).
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Figure 28: plot of disease-related connectivities (WNL, weighted number  
of  links)  versus  global  connectivities  (TIS,  Total  Interactions  Score).  
Calculated Leader Genes are above the regression tendency line. 
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In the second part of our work we investigated the link between microRNAs 
and leader genes. 
microRNAs  (miRNAs)  are  a  family  of  small  and  short  (usually  19-25 
nucleotides  long),  single-stranded,  endogenous,  non-coding  RNA 
molecules.  They  intervene  at  a  post-transcriptional  level  of  the  gene 
regulation and expression, binding with a certain degree of complementarity 
to the 3’-untranslated region (UTR) of different target mRNAs. This results 
in degradation of the target molecule via site cleavage or protein translation 
inhibition  or  perturbation,  or  both  [Lee,  2013].  Because  of  their  unique 
regulatory  properties,  miRNAs  are  supposed  to  play  a  major  role  in 
embryogenesis and throughout the different developmental stages, as well 
as  in  the  regulation  of  the  cell  cycle  and  growth,  proliferation, 
differentiation,  and apoptosis.  For this  reason, they can be considered as 
important biomarkers and new potential therapeutic biotargets in oncology 
[De Cecco et al., 2013] and in pathology. 
The  role  of  miRNAs  in  oral  diseases  is  emerging,  since  evidences  are 
growing  and  accumulating  in  favor  of  this  hypothesis.  For  example, 
miRNAs  circulating  in  peripheral  blood  and in  serum [Maclellan  et  al., 
2012], as well tissutal and salivary miRNAs (Gallo et al., 2013) can be used 
as helpful biomarkers of early-stage oral cancer [Yoshizawa et al., 2013]. 
Salivary miRNAs are transported in vesicles called exosomes, that preserve 
their stability [Michael et al., 2010; Ogawa et al., 2013]. In particular, the 
interest in studying salivary microRNAome is increasing because of the non 
invasivity  and  effectiveness  of  the  procedure,  and  also  because  of  the 
advancement  in  salivary  diagnostic  technologies  [Baum  et  al.,  2011; 
Burbelo et al., 2012; Patel et al., 2011; Wong et al., 2011]. Several scholars 
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maintain  the  importance  of  integrating  it  with other  diagnostic  alphabets 
(namely transcriptomics, proteomics, metabolomics and oral microbiomics), 
that constitute the five pillars of a new, recently emerging approach to oral 
diseases called “salivaomics” [Wong, 2012] and more generally speaking 
“oralomics” [Arrais et al., 2013; Rosa et al., 2012].
The importance of the omics studies in medicine and in dentistry is that they 
could enable a personalized treatment  of the disorders [Eng et  al.,  2012; 
Garcia et al., 2013; Glick et al., 2012; Nicolini et al., 2012].
However,  notwithstanding  the  importance  of  incorporating  the  oral 
microRNAome in the omics-based study of oral pathologies, so far only few 
miRNAs  related  to  them  have  been  discovered  and  described  in  the 
literature. Most published studies focus on oral cancer, while for example 
gingival and periodontal disorders are less studied.
The aim of the data-mining based approach that we introduce in this second 
part  of  our  research  dedicated  to  OLP is  to  accelerate  and  facilitate 
discoveries in the field of oral diseases.
We  use our previously found Leader genes in order to predict  putatively 
associated miRNAs, exploiting the miRGene database..
miRNAs indeed could act as important biomarkers of OLP. 
Many biomarkers useful for predicting the evolution to cancer are emerging, 
including  the  pentaspan  transmembrane  glycoprotein  CD133 (Sun et  al., 
2013), matrix metalloproteinases like  MMP1, MMP2 (Chen et al., 2008; 
Sutinen et al., 1998), MMP7 and their inhibitors, TIMP1, TIMP2 (Chen et 
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al., 2008; Sutinen et al., 1998), interleukins and cytokines such as IL1-alpha 
(Rhodus et al., 2005), IL6 and IL8 (Lisa Cheng et al., 2013; Rhodus et al., 
2005). 
Also  apoptosis  and  cellular  proliferation  markers  have  been  extensively 
investigated: the oncogenes p53 [Agha-Hosseini and Mirzaii-Dizgah, 2013; 
de  Sousa  et  al.,  2009;  Ebrahimi  et  al.,  2008,  2011;  Leyva-Huerta  et  al., 
2012;  Ogmundsdóttir  et  al.,  2009a;  Ogmundsdóttir  et  al.,  2009b] and c-
erbB2 [Kilpi et al., 1996], CDK4, p16 [Poomsawat et al., 2011], BAX [de 
Sousa  et  al.,  2009],  BCL-2 [de  Sousa  et  al.,  2009;  Leyva-Huerta  et  al., 
2012], TNF and its receptor [Rhodus et al., 2005; Younes et al., 1996] and 
Proliferating-cell nuclear antigen or PCNA [Martinez-Lara et al., 1996].
Integrins and integrin-like proteins, growth factors are other molecules that 
could  be  involved  in  the  process  of  carcinogenesis:  alpha-9-integrin 
[Häkkinen  et  al.,  1999],  laminin-5  or  kalinin  [Kainulainen  et  al.,  1997], 
endothelin-1 [Cheng et al., 2011], podoplanin and ABCG2 [Shi et al., 2010], 
desmocollin  type  1  [Mattila  et  al.,  2008],  and TGF-beta-1  [Chen  et  al., 
2008].
Other interesting and promising markers include COX2 [Li and Cui, 2013; 
Pandey  et  al.,  2008],  OAZ1,  S100P,  and  DUSP1  [Cheng  et  al.,  2013], 
aldehyde  dehydrogenase  type  1 [Xu et  al.,  2013],  and BMI1 [Ma et  al., 
2013].
LCK,  survivin  and  PI-3K  are  other  emerging  biomarkers  of  the  pre-
malignant nature of OLP [Oluwadara et al.,  2009], suggesting that LCK-
inhibitors could be useful .
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Besides  genetic  imbalances,  alterations  and  polymorphisms,  behavioral 
lifestyle factors such as tobacco smoking and chewing, nutrition, infectious 
agents like HPV [Syrjänen et al., 2011] or HCV [Carrozzo and Gandolfo, 
2003],  environmental  and  occupational  factors,  psychological  state  like 
stress  [Prolo  et  al.,  2002;  Valter  et  al.,  2013]  may  play  a  role  in  the 
pathogenesis of OLP.
Annual  screening  for  early  oral  cancer  detection  [Mattsson et  al.,  2002; 
Nagao and Warnakulasuriya, 2003] and personalized plaque controls (Stone 
et al., 2013) have been proposed as preventive approaches since a complete 
healing from OLP is very rare, and so far there insufficient evidences about 
the best treatment for OLP, even though corticosteroids are wide use for the 
management  of this  disease [Lodi et  al.,  2012].  Other treatments  include 
retinoids,  photochemotherapy [Pavlic and Vujic-Aleksic, 2013], and laser 
therapy [Boorghani et al., 2010].  
In order to predict the potential miRNAs network related to OLP, we used 
our previously identified “leader genes” [Orlando et al., 2012], namely both 
the Class A genes (JUN, EGFR, FOS, IL2, and ITGB4) and the Class B 
genes (CASP3, CD247, IL2RA, IFNG, MMP2, LAMC2). Then, we mined 
the  miRGen  database  using  the  “Targets”  option  (available  at 
http://www.microrna.gr/mirgen).  This  software  relies  on  a  relational  database 
technology and enables a comprehensive research, integrating both the most 
widely  used  databases  and  repositories  with  the  list  of  experimentally 
validated  miRNAs  and  the  bioinformatics  tools  for  the  microRNAs 
prediction  (namely,  DIANA-microT,  miRanda,  miRBase,  PicTar,  and 
TargetScanS) [Alexiou et al., 2010; Megraw et al., 2006]. 
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Topological properties of the obtained graphs portraying the OLP-related 
microRNAomes have been also studied.   
As mentioned before, only few studies in the literature report OLP-related 
miRNAs. These articles (Dang et al., 2013; Danielsson et al., 2012a, 2012b; 
Gassling  et  al.,  2013;  Hu  et  al.,  2013;  Zhang  et  al.,  2012)  have  been 
reviewed and summarized in Table 5. All the  in silico predicted miRNAs 
are reported in Table 6 for Class A leader genes-related molecules and in 
Table 7 for the Class B leader genes-related miRNAs.
miRNAs  that  have  been  already  experimentally  validated  represent  the 
32.26% (10/31) of the entire list.
Class A leader genes-related miRNAs predict the 42.19% (81/192) of the 
OLP + oral diseases-associated miRNAs validated in the literature.
miRNAs that have been already found to be associated with OLP are the 
32.26% (10/31) of the entire list.
Class B leader genes-related miRNAs predict the 46.03% (58/126) of the 
OLP + oral diseases-associated miRNAs validated in the literature.
Taken together the Class A and Class B leader genes-related miRNAs, they 
can predict the 48.39% (15/31) of the OLP and the of OLP + oral diseases-
associated miRNAs validated in the literature.
The  entire  OLP-related  microRNAome  is  too  complex  to  be  properly 
studied (shown in Figure 29), since the number of nodes and edges of the 
graph is overwhelming.  For this  reason, after  using a holistic and highly 
integrated  approach,  a  reductionist  methodology  should  be  exploited  in 
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order to underpin a more essential panel of miRNAs, that could be better 
investigated and elucidated via ad hoc targeted experiments. 
From the  topological  analysis  (summarized  in  Table  5),  the  two  graphs 
representing the Class A and Class B-related microRNAomees appear to be 
the most significant part of the entire microRNAome graph, being the bulk 
of  it  in  term  of  network  diameter  and  radius,  network  centralization, 
topological  density  and  clustering  coefficients,  while  preserving  other 
topological  parameters  (such as the scale-free behavior,  the characteristic 
path length and the percentage of shortest paths) (Figures 30, 31). 
In  conclusion,  microRNAs  (miRNAs)  are  a  family  of  small  and  short 
(usually 19-25 nucleotides long), single-stranded, endogenous, non-coding 
RNA molecules. They play a key role both in physiology and in pathology, 
and  their  role  in  oral  diseases  is  emerging.  Here  we  introduce  a 
biomolecular strategy for predicting diseases-related miRNAs, based upon 
our  previous  published  “Leader  Genes  algorithm”.  We  managed  to  find 
most of the already established OLP-related miRNAs. Moreover, we found 
also other miRNAs that have not been directly linked with OLP yet but have 
a role in other oral diseases. For the remaining miRNAs their role is still 
unknown. This biomolecular strategy can foster further research in the field 
of the biology of oral diseases, suggesting to the researchers and molecular 
biologists  some targets  to  focus  on and to  explore  with  ad hoc targeted 
experiments.  
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TOPOLOGICAL 
PARAMETER
ENTIRE OLP-
RELATED 
microRNAome
CLASS A Leader 
Genes-RELATED 
microRNAome
CLASS B Leader 
Genes-RELATED 
microRNAome
Clustering 
coefficient
0.19 0.96 0.73
Network diameter 3 2 2
Network radius 2 1 1
Network 
centralization
0.94 0.99 0.99
Shortest paths (%) 99 99 99
Characteristic path 
length
1.99 1.99 1.99
Average number of 
neighbors
41.49 5.78 7.7
Network density 0.04 0.01 0.01
Table 5: comparison of the topological properties among the entire OLP-
related microRNAome, and the ones associated to Class A and B leader  
genes. 
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Figure 29: the entire OLP-related microRNAome.
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Figure 30: the topological properties of the OLP-related microRNAome.
121
Chapter 6. Medical applications
 Figure 31: the leader genes-based OLP-related microRNAome.
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6.3. NAPPA-BASED QCM APPLICATION IN ONCOLOGY
We built  a  prototype  version  of  our  NAPPA-based biosensor  with  each 
quartz containing 16 (4x4) NAPPA spots of 300-micron square in order to 
synthetize functional proteins in situ directly from printed cDNAs (comple-
mentary DNAs) just before the assay [Nicolini et al., 2012a; Nicolini et al., 
2012b; Spera et al., 2013].
Quartzes'  gold  surfaces  were  coated  with  cysteamine  to  allow  the 
immobilization of the NAPPA printing mix. 
Briefly, quartzes were washed three times with ethanol, dried with Argon 
and incubated over night at 4°C with 2mM cysteamine. Quartzes were then 
washed three times with ethanol to remove any unbound cysteamine and 
dried with Argon. 
Plasmids DNA coding for GST tagged proteins were transformed into  E. 
coli and DNA were purified using the NucleoPrepII anion exchange resin 
(Macherey Nagel). NAPPA printing mix was prepared with 1.4μg/ul DNA, 
3.75μg/ul  BSA (Sigma-Aldrich),  5mM BS3 (Pierce,  Rockford,  IL,  USA) 
and 66.5μg polyclonal capture GST antibody (GE Healthcares). 
Negative controls,  named master  mix (hereinafter  abbreviated as “MM”), 
were obtained replacing DNA for water in the printing mix. Samples were 
incubated at room temperature for 1 hour with agitation and then printed on 
the cysteamine-coated gold quartz using the Qarray II from Genetix. 
As test proteins, we used p53 and MDM2. These monitored proteins are of 
fundamental importance in the molecular mechanisms leading to malignant 
cell  transformation  and  cancer;  p53  is  in  fact  a  53-kiloDalton 
phosphoprotein oncosuppressor, encoded by a 20-kilobases gene situated on 
the short arm of human chromosome 17 and termed as the “guardian of the 
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genome” and the “policeman of  oncogenes”  [Efeyan  and Serrano,  2007; 
Levine, 1997]. Mutated, it is involved in up to 70% of human tumors, being 
responsible of cell growth arrest,  senescence,  apoptosis in response to an 
array  of  stimuli  such  as  DNA damages  (DSB,  or  double-strand-breaks), 
hypoxia, telomeres shortening, cell adhesion, oncogene activation and other 
molecular and cellular stresses [Vousden and Lu, 2002]. 
MDM2,  a  p53-specific  E3  ubiquitin  ligase,  inhibits  p53  functions  by 
binding to its  N-terminal  transcription-promoting domain,  thus having an 
oncogenic activity. The MDM2-p53 plays a major role in cancer, being also 
a molecular therapeutic target and its monitoring is of crucial importance in 
cancer diagnosis and treatment [Shangary and Wang, 2008].
Table  6:  peak  frequency  (f),  half-width  at  half-height  (Γ),  maximum 
conductance increment (YRE), and normalized D factor for the impedance  
curves shown in Figure  90 left.
 Impedance Curve f (Hz) Γ (Hz) YRE (mS) DN (Hz/mS) 
beginning 9475435 2220 0,42 10699
After protein expression and washing 9470905 3705 0,31 23903
After MDM2 addition 9467860 3600 0,14 53333
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Figure 32: (Left) p53 quartz impedance curves recorded before the gene  
expression (solid  curve),  after  the  protein  expression and the  washing  
process (dashed curve) and after MDM2 addition (dotted curve); (Right)  
p53 quartz frequency variation in real time; at time  t = 600 s a MDM2 
solution (50 μM in PBS) was injected in the flow chamber.
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Figure  33:  NAPPA  expression  for  the  individual  CDK2  (left),  P53  
(middle) and combined P53 and CDK2 genes (right) on each individual  
quartz.  The blue curves were acquired before the expression of NAPPA,  
while the red curves were acquired after the protein expression/capture  
and washing process. The curves have been centered to their maximum  
frequency to better visualize the changing in bandwidths and maximum of  
conductance.  
In  order  to  enhance  the  sensitivity,  each  quartz  was  printed  with  100 
identical  features  of  300 microns  diameter  each,  spaced by 350 microns 
center-to-center. 
The human cDNAs immobilized on the NAPPA-QC were: CDK2 (Cyclin-
Dependent Kinase 2), CYP11A1 (Cytochrome P450, Family 11, Subfamily 
A,  Polypeptide  1),  Jun,   MLH1  (mutL  homolog  1),  p53,  and  polD1 
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(Polymerase (DNA Directed), Delta 1, Catalytic Subunit). The size of those 
proteins ranged from 61 kDa to 150 kDa, including the 27 kDa GST tag.
Gene expression was performed immediately before the assay, following the 
protocol described as modified from [Festa et al., 2013].
Briefly,  in vitro transcription and translation were performed using human 
IVTT mix  (1-Step  Human  Coupled  IVTT Kit,  Thermo  Fisher  Scientific 
Inc.),  prepared  according  to  the  manufacturers’  instructions.  The  quartz, 
connected to the nanogravimeter inside the incubator, was incubated for 1.5 
hr at 30°C with 40μl of HeLa lysate mix for proteins synthesis and then, the 
temperature was decreased to 15°C for a period of 30 min to facilitate the 
proteins  binding  on  the  capture  antibody  (anti-GST).  After  the  protein 
expression and capture, the quartz was removed from the instrument and 
washed at room temperature, in PBS for 3 times. The quartz was then placed 
in the flux chamber for protein-protein interaction analysis.  The protocol 
described above was followed identically for both negative control QC (the 
one with only MM, i.e, all the NAPPA chemistry except the cDNA) and 
protein displaying QC.
After protein expression and capture, the QCs were washed and used for the 
interaction studies as follows: QC displaying Jun was exposed to a flow of a 
33 μM ATF2 (Sigma-Aldrich) solution in PBS (for flow interaction at 0.02 
ml/min flow rate) for 10 minutes  at  22°C; alternatively 60 µl of 33 µM 
ATF2 solution in PBS was added on the QC surface (for static interaction) 
for 10 minutes at 22°C.
We also tested the possibility to analyze protein-protein interactions in QC 
displaying  multiple  proteins.  For  this  aim,  we  co-printed  cDNA  for 
Jun&CDK2 and Jun&CDK2&p53 on a single QC and after the expression a 
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mixture of these proteins was displayed on the QC surface. We analyzed the 
interaction response to  ATF2 on both NAPPA-expressed QCs. It  is  well 
known that the proto-oncoprotein c-Jun is a major dimerization partner of 
ATF2, and c-Jun–ATF2 heterodimers are important for many cellular and 
neoplastic processess [Hai and Curran, 1991; Liu et al., 2006]. 
On the contrary,  no interactions are known between ATF2 and CDK2 or 
p53. 
We analyzed  the  interaction  between CYP11A1 and cholesterol,  both  in 
solution and in blood, to acquire information on the binding kinetics6. After 
protein expression and capture CYP11A1 expressing QC was positioned in 
the  flow chamber  and  exposed to  a  flow of  a  50  μM Cholesterol  (Sig-
ma-Aldrich)  solution  in  30%  sodium  cholate  (Sigma-Aldrich),  at  0.02 
ml/min flow rate,  for 10 minutes at 22°C. We used cytochrome P450scc 
(CYP11A1) for the detection of Cholesterol (Sigma-Aldrich) because of its 
specificity.  As  negative  control  we  analyzed  the  interaction  between 
Clompiramine and polD1 and MLH1. MLH1 is a protein involved in DNA 
mismatches repair and polD1 is a DNA polymerase. Noone of these protein 
should interact with Clomipramine.  
Various kinetic models have been developed to describe protein-protein and 
protein-small molecules interactions.. For our data, on the base of the results 
of  [Turon  et  al.,  2008],  we  performed  mathematical  modelling  of  the 
protein-protein interaction, assuming a saturation like kinetics, that is to say 
a  quasi-steady-state  condition  model.  For  this  purpose,  we  used  the 
following  experimental  equation  [Turon  et  al.,  2008]  based  on  an 
exponential decay function instead of using deterministic models, focusing 
on frequency variation: 
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Δf = Mmax(1 – e–τ/t),  
where  Δf  is the frequency variation (in Hz),  Mmax is the maximum binding 
value  in  hertz  (corresponding  to  the  minimum  frequency  measured,  or 
plateau value), τ is the relaxation time (expressed in reciprocal minutes) that 
is the reciprocal of the enzyme protein adsorption/interaction rate , and t is 
the time (in minutes). 
The sensitivity of our NAPPA based biosensor was determined by the QC 
characteristics and the sensitivity of the nanogravimeter. At the moment, the 
minimum frequency shift detectable is of 0.05 Hz that corresponds to about 
0.3 ng of detected molecules [Spera et al., 2013].
QCM_D measures were calibrated for frequency and for D factor shifts. The 
frequency calibration was performed using different amounts of thaumatin. 
The calibration curve equation (obtained with Ordinary Least Squares meth-
ods, OLS) is: 
Δf= - 7.16 – 231.18 m;  
with r2= 0.9986. 
The  D  factor  calibration  in  function of  the viscosity was obtained using 
fructose samples at different concentrations. The calibration curve equation 
(obtained with OLS methods) is: 
D = 0.831 + 0.286 η; (equation 5)
with  r2= 0.9990.  For both the curves,  a good correlation  with the linear 
slope was found3, 6.
We analyzed the conductance curves acquired in NAPPA-QCs in different 
steps of the expressing and capturing process. Coefficients of variation (CV) 
have been computed for each conductance curve, according to the following 
equation:
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CV = σ / µ;  
where σ  is the standard deviation and µ the mean.
Figure 33 shows the conductance curves for three NAPPA-QCs expressing 
p53, CDK2 or a mixture of p53 and CDK2 (both cDNAs were co-immobil-
ized in each feature). The blue curves were acquired before the expression 
of  NAPPA  while  the  red  curves  were  acquired  after  the  protein 
expression/capture and washing process. The curves have been centered to 
their  maximum frequency to better  visualize the changing in bandwidths 
and conductance. These data pointed to a unique conductance curve shape 
for each protein and suggested the possibility to identify the expressed pro-
teins by QCM-D even when combined on the same expressing QC (Figure 
3).
To test the possibility to acquire information on the kinetic constant of a 
protein-small molecule interaction we generated a NAPPA-QC expressing 
CYP11A1 to be tested for cholesterol interaction as proof of principle. The 
P450scc-cholesterol interaction, in fact, is well characterized and the results 
obtained have been satisfactorily  compared with those in  literature [Ant-
onini et al., 2004; Arya et al., 2008; Nicolini et al., 2001; Shumyantseva et 
al., 2004; Stura et al., 2007].  
In Figure 4 are reported the conductance curves for the negative control 
(MM) or CYP11A1 expressing NAPPA-QC arrays. The conductance curves 
were acquired in different steps of NAPPA expression process. In particular: 
 Before the beginning of the gene expression process (“Baseline”, 
the NAPPA-QC is dry); 
 After  the  addition  of  human  IVTT  lysate  at  30°C  (“IVTT 
addition”), i.e. prior protein expression; 
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 After  90 minutes  from the addition  of  human IVTT lysate,  i.e. 
after protein expression (“90 min IVTT addition”); 
 After 120 minutes from the addition of human IVTT lysate, i.e. at 
the end of QC incubation at 15°C, which is the capture step (“Post-capture 
(30 min)”);
 After the final washing process with PBS (“Post-wash”).
At the end of the entire expression process, the CYP11A1 expressing QC 
was positioned in the flow chamber and exposed to a flow of a 50 μM Cho-
lesterol  solution  in  30%  sodium  cholate.  The  conductance  curve 
“MM+CYP11A1+cholesterol” (see Figure 4b) was recorded in this condi-
tion. 
In table 6 are reported the main parameters of the conductance curves of 
Figure 32, 33. 
Table 7: Main parameters of QC-NAPPA displaying no proteins (MM) or  
CYP11A1.   Conductance  curves  were  collected  in  different  steps  of  
NAPPA protocol.
 f (Hz) a Γ (Hz) a Gmax (mS)a D *10
3b DN 
(Hz/mS)b
MM Conductance curves
Baseline 9497485 2422 0.432 0.51 11218
IVTT addition 9493570 4562 0.370 0.96 24653
90 min IVTT addition 9493495 4500 0.390 0.95 23071
Post-capture (30 min) 9493120 4875 0.378 1.03 25814
Post-wash 9489085 6255 0.046 1.32 273144
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CYP11A1 Conductance curves
Baseline 9487615 2265 0.440 0.48 10286
IVTT addition 9481540 4198 0.399 0.87 21069
90 min IVTT addition 9479935 3984 0.401 0.84 19895
Post-capture (30 min) 9479790 3980 0.400 0.84 19895
Post-wash 9475975 5625 0.150 1.19 75050
MM+CYP11A1+ cholesterol 9478300 6410 0.268 1.35 47782
a f is peak frequency, Γ is the half-width half-maximum and Gmax is the max conductance.
bD factor and DN = 2Γ/Gmax normalized D factor.
It is evident the decrease in the frequency (f) due to the human IVTT lysate 
addition.  There  is also a change in viscoelastic properties of the quartzes 
after the human IVTT lysate addition, leading to a measurable increase of 
the bandwidth (Γ). During the incubation, on the contrary, the frequency and 
bandwidth variations were minimal. This effect could be related to two main 
effects: first merely due to the IVTT lysate addition on the QC surface - 
when the QC comes in contact with a solution the frequency decreases de-
pending upon the viscosity and the density of the solution, and there is a 
decrement in damping the resonant oscillation 47- and the second due to the 
change of the composition of both QC surface and IVTT lysate after the 
gene expression and the protein synthesis and immobilization. The conduct-
ance curves acquired after PBS washing evidenced the further changes of 
solution in contact with the QC.
In tables 7, 8 is reported the shift of the main parameters normalized against 
the “Baseline” conductance curve and the conductance curve acquired after 
132
Chapter 6. Medical applications
human IVTT lysate (“IVTT addition”). It is also reported the mass of mo-
lecules immobilized on the QC surface at the end of immobilization pro-
tocol and after the interaction with Cholesterol (m), estimated through the 
calibration coefficients.
Table 8 Shift of the main parameters of MM and CYP11A1 conductance  
curves after lysate addition and the corresponding mass of immobilized  
protein on the QC surface. 
MM Conductance 
curves Cv
a ΔDb
ΔDN  
(Hz/
mS)b
Δf 
(Hz)c
Δf’ 
(Hz)c
m 
(μg) c
m’ 
(μg) c
IVTT addition 3.3% - - -3915 - 17,0 -
90 min  IVTT addi-
tion 4.1% -0.01 -1582 -3990 -75 17,3 0,4
Post-Capture  (30 
min) 4.0% 0.07 1161 -4365 -450 18,9 2,0
a Coefficient of variation of three independent experiments..
b D factor and normalized D factor shifts (ΔD and ΔDN) respect the values 
immediately after lysate addition 
c Frequency shifts respect the initial  frequency (Δf) and respect the fre-
quency immediately after lysate addition (Δf’) and corresponding molecu-
lar masses (m and m’).
CYP11A1 
Conductance 
curves
Cva ΔDb
ΔDN  
(Hz/
mS)b
Δf 
(Hz)c
Δf’ 
(Hz)c
m 
(μg) c
m’ 
(μg) c
IVTT addition 4.8% - - -6075 - 26.3 -
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90  min  IVTT  addi-
tion 4.8% -0.03 -1174 -7680 -1605 33.3 7.0
Post-Capture  (30 
min) 4.6% -0.03 -1174 -7825 -1750 33.9 7.6
MM+CYP11A1+ 
cholesterol 6.9% 0.48 26713 -9315 -3240 40.3 14
a Coefficient of variation of three independent experiments..
b D factor and normalized D factor shifts (ΔD and ΔDN) respect the values 
immediately after lysate addition 
c Frequency shifts respect the initial  frequency (Δf) and respect the fre-
quency immediately after lysate addition (Δf’) and corresponding molecu-
lar masses (m and m’).
To estimate the amount of proteins anchored on the QC surface after the 
NAPPA expression we had to account for the human IVTT lysate molecules 
aspecifically adsorbed on the quartz surface. Assuming that on each QC sur-
face there was the same aspecific adsorption we could estimate it from ref-
erence quartz conductance curves. In particular we considered the frequency 
shift between the reference QC conductance curves acquired immediately 
after the human IVTT lysate addition (”IVTT addition”) and that acquired at 
the end of the protein anchorage (“90 min IVTT addition”); this value is 450 
Hz (see table 1), that correspond to 2 μg of molecules aspecifically adsorbed 
(see tables 7, 8). The values of immobilized CYP11A1 molecules, therefore, 
was 5.6 μg – obtained subtracting 2 μg of molecules aspecifically adsorbed 
to the 7.6 μg of molecules adsorbed in correspondence of “Post-Capture (30 
min)” curve (see table 2) - while the amount of Cholesterol was 6.4 μg – ob-
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tained subtracting 5.6 μg of CYP11A1 proteins captured on the array and 2 
μg of molecules  aspecifically adsorbed from the 14 μg of molecules  ad-
sorbed in correspondence of “MM+CYP11A1+ cholesterol” curve. We veri-
fied (data not reported) that the exposure of the QC to sodium cholate solu-
tion affected only the bandwidth of the curve, considerably increasing the D 
factor, leaving the resonance frequency unchanged. This result  also served 
as control to verify the stability of the biosensor.
Figure 34: conductance curves of MM QC (upper) and of CYP11A1 QC 
(lower). The curves were collected in different steps of NAPPA protocol,  
as reported in the legend, and after the addition of cholesterol. In the box  
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the  MM+CYP11A1+cholesterol  conductance  curves  acquired  with  
frequency acquisition steps of 1 Hz. 
Our QCM_D instrument gave us the opportunity to monitor in real-time the 
trend of D factor and f. In Figure 34 we reported frequency vs. time during 
the interaction between CYP11A1 and Cholesterol, both in solution (as pre-
viously reported) and in blood. We obtained a K of about 100 µM, a value 
in good agreement with the values found in the literature.  
In the first experiments conductance curves were acquired every 5 minutes 
(data non reported) and it was noticed that 15 minutes after IVTT lysate ad-
dition at 30°C the position and shape of the curves did not change until we 
decrease the temperature to 15°C. After few minutes at 15°C again position 
and shape of the curves did not change until the washing step. Deducing 
from these results that the protein expression took place in the first minutes 
and that also their capture needed only few minutes we decided, then to per-
form next experiments reducing the expression time from 90 minutes to 15 
minutes (at 30°C) and the capture time from 30 to 5 minutes (at 15°C).
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 Figure 35:  FLOW interaction CYP11A1 with HDL cholesterol in blood  
(upper panel) and in solution (lower panel).
To test the possibility to analyze multi-protein interactions we immobilized 
on the same QC both Jun and CDK2 cDNAs and tested the response to 
ATF2 interaction. c-Jun is a partner of ATF2 in many cellular processes38, 
however no interaction are known between CDK2 and ATF2.
The conductance curves of NAPPA-QC expressing Jun&CDK2 acquired in 
different  steps  of  NAPPA expressing  process  are  reported  in  Figure  6a. 
After protein expression and capture the Jun&CDK2 expressing QC was po-
sitioned in the flow chamber and exposed to a flow of 33 μM ATF2 solution 
in PBS. The conductance curve “MM+Jun&CDK2+ATF2” (Figure 35) was 
recorded after 3 minutes of flux. In Table 9 are reported the main paramet-
ers of conductance curves of Figure 6a.
Table  9: main parameters of QC-NAPPA displaying Jun&CDK2. Con-
ductance curves were collected in different steps of NAPPA protocol.
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In table 10 is reported the shift of the main parameters normalized against 
the conductance curve acquired immediately after human IVTT lysate addi-
tion (“IVTT addition”). Through equation 5 we evaluated the mass of im-
mobilized proteins on the quartz surface at the end of capture protocol and 
after the interaction with ATF2 (m’).
Table 10: shift of the main parameters of Jun&CDK2 conductance curves  
after  lysate  addition  and  after  protein-protein  interaction,  and  relative  
mass of immobilized proteins on the quartz surface.
Jun&CDK2 Conductance curve Cva DDb DDN  (Hz/mS) b Df’ (Hz)
 b m’ (μg) c
5 min IVTT addition 5.5% -0.03 -455 -456 2.0
Jun&CDK2 Conductance curves f (Hz)a Γ (Hz) a Gmax (mS) a D *10
3 b DN 
(Hz/mS) b
IVTT addition 9482473 3073 0.461 0.65 13336
5 min IVTT addition 9482145 2945 0.457 0.62 12885
15 min IVTT addition 9481600 2800 0.447 0.59 12528
Post-capture (5 min) 9481018 2836 0.410 0.60 13822
Post-wash 9479200 2400 0.261 0.51 18391
PBS-flux 9480764 2909 0.313 0.61 18577
MM+Jun&CDK2+ATF2 9481309 2982 0.294 0.63 20284
a f is peak frequency, Γ is the half-width half-maximum and Gmax is the max conductance.
b D factor and DN = 2Γ/Gmax normalized D factor.
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15 min IVTT addition 5.7% -0.06 -660 -807 3.5
Post-capture (5 min) 5.3% -0.06 509 -1432 6.2
Post-wash 4.8% -0.28 45965 -3895 17.0
PBS-flux 7.3% -0.21 11182 -2561 -5.8*
MM+Jun&CDK2+ATF2 8.0% -0.20 9644 -2491 -6.1*
a  Coefficient of variation. We performed three independent experiments.
b D factor, normalized D factor and frequency shifts (DD, DDN and Df’) with respect the values 
immediately after IVTT lysate addition (see table 3). 
c Mass of molecules immobilized on the quartz surface for each step (calculated by equation 5).
* These values were obtained considering the frequency shifts respect “Post-wash” curve, since 
the QC was in contact with PBS solution.
The amount of molecules captured on the QC 5 minutes after protein cap-
ture corresponded to about 6 µg. A further frequency decrease was recorded 
after the washing. This decrease was not due to further molecules capture on 
the QC surface but rather to the change of the solution in contact with the 
QC surface,  since the frequency is  dependent  upon the viscosity and the 
density of the solution. This effect is mostly evident considering the shift in 
D and normalized  D factor. In particular post wash DDN increase of about 
100 times. What is meaningful is the frequency shift after QC exposure to 
ATF2 flux. We recorded, in fact,  a frequency increase,  rather than a de-
crease as expected. Evidently the flux, even if very gentle, caused spoliation 
of the QC, removing some captured molecules and making impossible to as-
sess the interaction between Jun and ATF2.
In order to overcome the spoliation problem, the interaction between Jun 
and AFT2 was tested in a static way, by simply adding the ATF2 solution 
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on the QC surface.  For this  experiment,  QC with immobilized cDNA of 
Jun&CDK2&p53 were expressed for a period of 90 minutes and captured 
for 30 minutes. After protein expression and capture, the QC was washed 
with PBS, and incubated for 10 minutes with 60 µl of 33 µM ATF2 solution 
in PBS.
In Table 11 are reported the main parameters of conductance curves of Fig-
ure 35 and in Table 12 is reported the shift of these parameters with respect 
those of the conductance  curve acquired  immediately after  lysate  human 
IVTT lysate addition (“IVTT addition”).
Table  11:  Main  parameters  of  QC-NAPPA displaying  Jun&CDK2&p53. 
The conductance curves were collected in different steps of NAPPA pro-
tocol.     
Jun&CDK2&p53 conductance curves f (Hz)a Γ (Hz) a Gmax (mS) a D *10
3 b DN 
(Hz/mS)b
Baseline 9489250 2375 0.436 0.50 10900
IVTT addition 9483250 4625 0.347 0.98 26629
10 min IVTT addition 9482625 4675 0.339 0.99 27543
80 min IVTT addition 9481750 4625 0.342 0.98 27038
Post-capture (30 min) 9481250 4688 0.300 0.99 31250
Post-wash 9477250 5375 0.111 1.13 97262
MM+Jun&CDK2&p53+ATF2 9475125 6000 0.188 1.27 63687
MM+Jun&CDK2&p53+ATF2 (10 min) 9475625 6063 0.187 1.28 64894
a f is peak frequency, Γ is the half-width half-maximum and Gmax is the max conductance.
bD factor and DN = 2Γ/Gmax normalized D factor.
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Table 12: Shifts of the main parameters of Jun&CDK2&p53 conductance 
curves after lysate addition and relative mass of immobilized protein on the 
quartz surface.
Jun&CDK2&p53 conductance curves Cv ΔD ΔDN  (Hz/mS) Δf’ (Hz) m’ (μg)
10 min IVTT addition 5.4% 0.01 914 -625 2.7
Post-expression (80 min) 6.0% 0.00 409 -1500 6.5
Post-capture (30 min) 5.5% 0.01 4621 -2000 8.7
Post-wash 5.2% 0.15 70633 -6000 26.2
MM+Jun&CDK2&p53+ATF2 6.5% 0.29 37058 -8125 9.2*
MM+Jun&CDK2&p53+ATF2 (10 min) 8.0% 0.30 38265 -7625 7.1*
a  Coefficient of variation. We performed two different experiments.
b D factor, normalized D factor and frequency shifts (DD, DDN and Df’) with respect the values 
immediately after IVTT lysate addition (see table 5). 
c Amount of molecules immobilized on the QC surface (calculated through equation 5 respect 
the frequency recorded immediately after IVTT addition).
* These values were obtained  considering the frequency shifts respect post-wash curve, since 
the QC was in contact with PBS solution.
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Figure 36: conductance curves of Jun and CDK2 expressing QC (upper  
panel). Conductance curves of Jun, CDK2 and p53 expressing QC (lower  
panel). The curves were collected in different steps of NAPPA process, as  
reported in the legends, and after the addition of ATF2 solution.
The unique conductance curve shape for each of the three proteins confirms 
the  possibility  to  identify the  three  expressed proteins  by QCM_D even 
when combined on the same expressing QC (Figure 37). 
Figure 37: matching of conductance curves of Jun expressing QC, CDK2  
expressing QC and p53 expressing QC after lysate addition.
The amount of molecules captured on the QC 90 minutes post-expression 
and 30 minutes post-capture corresponded to about 8 µg, not much different 
from 6 µg obtained in the previous experiments. Again a frequency decrease 
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was recorded after the washing (due to PBS solution). In contrast to what 
previously obtained, the frequency further decreased after QC exposure to 
ATF2  flux,  suggesting  that  the  interaction  between  Jun  and  ATF2  was 
favored by the static process. To evaluate the amount of ATF2 bound to Jun 
we  considered  the  frequency  shift  between  “post-wash”  and 
“MM+Jun&CDK2&p53+ATF2” curves, because in both conditions the QC 
was in the same solution (PBS) and any changes in the frequency is due to 
the binding of ATF2. The amount of ATF2 molecules bound to the QC was 
9.2 µg.
As negative  control  a  NAPPA-QC co-expressing  polD1 and MLH1 was 
tested for Clomipramine interaction. After protein expression and immobil-
ization and after PBS washing 60 µl of 110 µM Clomipramine solution in 
PBS was spotted on the polD1&MLH1 expressing QC. The conductance 
curve “MM+ polD1&MLH1+Clomipramine” (Figure 38) was recorded 1 
minute after Clomipramine solution addition.
In Table 13 are reported the main parameters of conductance curves of Fig-
ure 38 and in Table 14 are reported the shifts of these parameters with re-
spect to those of “IVTT addition” curve.
Table 13: main parameters of polD1&MLH1 conductance curves collected 
in different steps of NAPPA expression protocol.
polD1&MLH1 Conductance curves f (Hz)a Γ (Hz) a Gmax (mS) a D *10
3 b DN 
(Hz/mS) b
Baseline 9486895 2860 0.450 0.60 12710
IVTT addition 9486439 2702 0.441 0.57 12254
5 min IVTT addition 9486088 2596 0.431 0.55 12050
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15 min IVTT addition 9485463 2596 0.393 0.55 13219
Post-capture (5 min) 9483000 1509 0.051 0.32 58674
Post-wash 9484333 1877 0.157 0.40 23892
MM+polD1& MLH1+Clomipramine 9484404 1895 0.170 0.40 22354
a f is peak frequency, Γ is the half-width half-maximum and Gmax is the max conductance.
b D factor and DN = 2Γ/Gmax normalized D factor.
The amount of molecules captured on the QC 15 minutes after the expres-
sion and 5 minutes after the capture corresponded to about 15 μg (Table 14). 
A frequency decrease was recorded after the washing (due to PBS solution). 
After Clomipramine addition no significant frequency shift was recorded.
Table  14:  Shifts  of  the  main  parameters  of  polD1&MLH1 conductance 
curves after lysate addition and after protein-protein interaction, and relative 
amount of molecules immobilized on the quartz surface.
polD1&MLH1 conductance curves Cva ΔDb ΔDN  (Hz/mS) b Δf’ (Hz)
 b m’ (μg) c
5 min IVTT addition 4.8% -0.02 -204 -351 1.5
15 min IVTT addition 5.3% -0.02 965 -976 4.3
Post-capture (5 min) 6.0% -0.25 46420 -3439 15.0
Post-wash 5.2% -0.17 11638 -2106 9.2
MM+polD1&MLH1+Clomipramine 7.1% -0.17 10100 -2035 -0.3*
a  Coefficient of variation. We performed two different experiments.
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b D factor, normalized D factor and frequency shifts (ΔD, ΔDN and Δf’) with respect the values 
immediately after IVTT lysate addition (see table 9). 
c Amount of molecules immobilized on the QC surface (calculated through equation 5 respect 
the frequency recorded immediately after IVTT addition).
* These values were obtained considering the frequency shifts respect post-wash curve, since the 
QC was in contact with PBS solution.
This result confirms that no interaction occurs between polD1 or MLH1 and 
Clomipramine, as expected.
Figure 38 Conductance curves of polD1 and MLH1 expressing QC. The  
curves were collected in different steps of NAPPA process, as reported in  
the legend, and for polD1 and MLH1 expressing QC, after the addition of  
Clomipramine solution, as negative control.
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As reported in the literature CV values are usually very low, confirming the 
repeatability of the experiments and the validity and portability of the tech-
nique. In our hands, NAPPA-based QCM_D proved to have an intra-assay 
overall CV of 5 % (range 3.3 -8.0 %).   
In this second pafrt, we report and discuss some preliminary results of 
protein expression of genes related to cancer. Experiments have been carried 
out coupling Nucleic Acid Programmable Protein Array (NAPPA) with a 
recently  improved  nanogravimetric  apparatus  which  exploits  the  quartz 
crystal  microbalance  with  frequency  (QCM_F)  and  quartz  crystal 
microbalance  with  dissipation  monitoring  (QCM_D)  technologies.  The 
selected proteins are BRIP1, JUN and ATF2 and their role and biological 
roles will be discussed further in this chapter.   
We selected BRIP1, JUN and ATF2 for their clinical relevance.
FANCJ/BRIP1/BACH1  (Fanconi  anemia  complementation  group  J 
protein/BRCA1-interacting  protein  1/BRCA1-associated  C-terminal 
helicase 1) is a 1249 amminoacids protein involved in breast, cervical and 
ovarian cancers, as well as in Fanconi anemia, which is a genetic cause of 
anemia, leading to acute myelogenous leukemia or to bone marrow failure. 
It is a DNA-dependent ATPase and helicase of the family RecQ DEAH, 
which interacts with the BRCT repeats domain of BRCA1. As helicase, it 
has  an  important  role  in  preserving  the  chromatin  structure  and  in 
facilitating and driving the replication process. It is encoded by the locus 
17q22–q24, which is 184 kilobases long and has 19 exons, and is situated 
near to the locus encoding the BRCA1 protein.
JUN encodes the c-Jun protein, which is a well-known oncogene, being 
the putative transforming gene of avian sarcoma virus 17. It encodes indeed 
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a protein with a strong similarity to the viral protein. It is encoded by the 
locus 1p32-p31 and its alteration leads to several malignancies .
ATF2  gene  (chromosome  2q32)  encodes  a  505  amino-acids  long 
transcription  factor,  that  belongs  to  the  leucine  zipper  family  of  DNA-
binding  proteins.  Also  ATF2  is  an  important  component  of  signaling 
pathways whose alterations are a cause of malignant transformation .   
We  analyzed  the  conductance  curves  acquired  in  NAPPA-QCs  in 
different  steps  of  the  expressing  and  capturing  process,  for  each 
conductance curve for NAPPA-QCs expressing BRIP1 and JUN (before and 
after ATF2 addiction). The curves were acquired both before the expression 
of NAPPA and after the protein expression/capture and washing process. 
The  curves  have  been  centered  to  their  maximum  frequency  to  better 
visualize the changing in bandwidths and conductance. These data pointed 
to  a unique conductance  curve shape for each protein and suggested the 
possibility  to  identify  the  expressed  proteins  by  QCM-D  even  when 
combined  on  the  same  expressing  QC.  The  conductance  curves  were 
acquired in different steps of NAPPA expression process.     
Using the calibration coefficient, we estimated the amount of molecules 
immobilized  on the quartz  surface at  the end of immobilization  protocol 
(m).
The  values  of  immobilized  BRIP1 molecules,  therefore,  was  2.28  μg 
while the amount of JUN was 1.69 μg. In terms of molar concentration, we 
found 0.02 nM for BRIP1 (having a molar weight of ~130kDa) and 0.04 nM 
for JUN (having a molar weight of ~39kDa).
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Figure 39 Conductance curves of JUN expressing QC. The curves were  
collected in different steps of NAPPA process, as reported in the legend,  
and for JUN expressing QC, after the addition of ATF2 protein.
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7. CONCLUSIONS. 
In this thesis, we have presented the results obtained from bioinformatics 
and from applying  our  innovative  conductometer,  realized  by combining 
NAPPA technology with  QCM_D,  to  the  characterization  and  analytical 
quantification  of  protein  expression  and  protein-protein  interactions  in  a 
multiparametric way, taking advantage of the multiple information provided 
by the analysis of the conductance curves (i.e. conductance, viscoelasticity 
and adsorbed mass).   
In the case of the bioinformatics work we were able to properly prioritize 
genes, in order to select few of them, that being hub genes may prove to be 
clinically relevant and significant. Further clinical studies will be needed to 
confirm our findings.
In the case of the NAPPA-based biosensor,  we were able to find and 
obtain pieces of information that, as stated by Guerrini and collaborators 
[39],  until  today  very  few  quantitative  data  oncogenes  expression  are 
present in the literature, which presents only relative changes in magnitude 
orders during the carcinogenesis.   
The  multi-spot  feature  of  our  sensor  could  be  further  exploited  for 
investigating the multi-protein expression and protein-protein interactions, 
becoming more clinically relevant. In fact, not single biomarkers are able to 
capture  the diagnosis  and prognosis  of cancer,  but a  composite  panel  of 
proteins that could be properly detected via high-throughput sensors.
Future  perspectives  of  this  biosensor  regard  its  clinical  introduction  for 
assessing  cancer  prognosis  and  make  a  personalized  diagnosis  and/or  to 
deliver an individualized treatment. In particular, different mutations of the 
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selected genes will be evaluated in terms of protein instability, functioning, 
and clinical implications for cancer and other diseases prognosis.
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8.  APPENDIX  I:  TABLE  OF  RMSD  OF  PDB  INSULIN 
STRUCTURES FROM 4IHN LB INSULIN. 
INSULIN PDB 
CAPTION
RMSD 
DEVIATION 
FROM LB 
INSULIN
METHOD RESOLUTION
2C8R 0.06 Insuline (60 sec) and UV 
laser excited fluorescence
classical vapor hanging 
drop
1.50
2C8Q 0.10 Insuline (1 sec) and UV 
laser excited fluorescence
classical vapor hanging 
drop
1.95
3I3Z 0.12 Human insulin
microgravity
1.60
3I40 0.13 Human insulin
microgravity
1.85
3U4N 0.17 A novel covalently linked 
insulin dimer
1.98
2CEU 0.53 Despentapeptide insulin in 
acetic acid  (pH 2) 
1.80
1BEN 0.63 Human insulin
microgravity
1.40
1GUJ 0.65 Insulin at pH 2: structural 
analysis of the conditions 
1.62
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1HTV
promoting insulin fibre 
formation
Crystal structure of 
destripeptide (B28-B30) 
insulin
 1.90
1B9E 0.69 Human insulin mutant 
SERB9GLU
2.50
3E7Y
 
1TYL
0.70 Structure of human insulin
The structure of a complex of 
hexameric insulin and  4'-
hydroxyacetanilide 
1.60
 
1.90
1TYM 0.71 The structure of a complex of 
hexameric insulin and 4'-
hydroxyacetanilide 
1.90
3E7Z
 
3V1G
 
 
2VJZ
0.72 Structure of human insulin
Forestalling insulin 
fibrillation by insertion of 
a chiral clamp mechanism-
based application of 
protein engineering to 
global health
Crystal structure form 
ultalente insulin 
microcrystals
1.70
 2.20
 
1.80
       2VK0 0.73 Crystal structure form 
ultalente insulin 
2.20
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 2WS4
microcrystals
Semi-synthetic analogue of 
human insulin ProB26-DTI 
in monomer form
 1.90
      2WS0 
 
1LPH
0.74 Semi-synthetic analogue of 
human insulin 
NMeAlaB26-insulin at pH 
7.5
Lys(B28)Pro(B29)-human 
insulin
2.10
 
2.30
1G7B
2WRU
  
2WRX
 
2WS1  
0.75 1.3 A structure of T3R3 
human insulin at 100 K
Semi-synthetic highly active 
analogue of human insulin 
NME AlaB26-DTI-NH2
Semi-synthetic analogue of 
human insulin NMeAlaB26-
insulin at pH 3.0
Semi-synthetic analogue of 
human insulin NMeTyrB26-
insulin in monomer form
1.30
1.57
 
1.50
 
1.60
2WRV 0.76 Semi-synthetic highly active 
analogue of human insulin 
NMeHisB26-DTI- NH2 
2.15
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 2WRW Semi-synthetic highly active 
analogue of human insulin 
NMeHisB26-DTI- NH2 
  2.41
1G7A 0.77 1.2 A structure of T3R3 
human insulin at 100 K
1.20
3P2X 0.81 Insulin fibrillation is the 
Janus face of induced fit. A 
chiaral clamp stabilizes the 
native state at the expense 
of activity
2.00
2W44 0.82 Structure  DELTAA1-A4 
insulin
2.00
3V19 0.83 Forestalling insulin 
fibrillation by insertion of 
a chiral clamp mechanism-
based application of 
protein engineering to 
global health
2.00
2R36 0.84 Crystal structure of ni 
human ARG-insulin
2.00
3KQ6 0.85 Enhancing the therapeutic 
properties of a protein by a 
designed zinc-binding site, 
structural principles of a 
novel long-acting insulin 
analog
1.90
2OMI 0.91 Structure of human insulin 
cocrystallized with protamine
2.24
3IR0 0.94 Crystal Structure of Human 2.20
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Insulin complexed with 
Cu+2 metal ion
2QIU 1.01 Structure of Human Arg-
Insulin
2.00
1QIY 1.02 Human insulin hexamers 
with chain B His mutated 
to Tyr complexed with 
phenol
2.30
2OMG
 
2R35
2OM1
1.03 Structure of human insulin 
cocrystallized with 
protamine and urea
Crystal structure of RB 
human arg-insulin
Structure of human insulin 
in presence of thiocyanate 
at pH 6.5
1.52
 
2.08
1.97
3Q6E
1ZNJ
1.04 Human insulin in complex 
with cucurbit[7]uril
Insulin, monoclinic crystal 
form 
2.05
2.00
3P33 1.06 Insulin fibrillation is the 
Janus face of induced fit. A 
chiral clamp stabilizes the 
native state at the expense of 
activity 
2.30
 
 
157
Appendix
2R34 Crystal structure of MN 
human arg-insulin
2.25
2OM0
 
1OS3
1.07 Structure of human insulin in 
presence of urea at pH 6.5
Dehydrated T6 human 
insulin at 100 K
2.05
 
1.95
3BRR 1.10 Crystal Structure of Insulin 
in Complex with Sulfatide
1.70
3ILG
  
 
    3ZQR
 
1MSO
1.12 Crystal structure of human 
insulin Sr+2 complex
NME PheB25 insulin 
analogue crystal structure 
T6 Human Insulin at 1.0 A 
Resolution
1.90
 
1.90
  
1.00
3INC
 
1ZEG 
 
3TT8
1.13 Crystal structure of human 
insulin with Ni+2 complex
Structure of B28 Asp 
insulin complex with 
phenol 
Crystal Structure Analysis 
of Cu Human Insulin 
1.85
 
1.60
 
1.12
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3EXX
Derivative
Structure of the T6 human 
insulin derivative with 
nickel at 1.35 A resolution
 
1.35
2OMH 1.14 Structure of human insulin 
cocrystallized with ARG-
12 peptide in presence of 
urea
1.36
1QJ0 1.16 Human insulin hexamers 
with chain B His mutated to 
Tyr 
2.40
3ZU1 1.17 Structure of LysB29(N 
epsilon omega-
carboxyheptadecanoyl)des(B
30) human insulin 
1.60
2WS6
 
3ROV
 
1QIZ
1.19 Semi-synthetic analogue of 
human insulin NME TyrB26-
insulin in hexamer form
Insulin's biosynthesis and 
activity have opposing 
structural requirements: a 
new factor in neonatal 
diabetes mellitus
Human insulin hexamers 
with chain B His mutated to 
Tyr complexed with 
resorcinol 
1.50
 
2.30
 
2.00
1XDA 1.21 Structure of insulin 1.80
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2OLZ 1.22 Structure of human insulin 
in presence of thiocyanate 
at pH 7.0
1.70
2OLY 
2WS7
1.23 Structure of human insulin in 
presence of urea at pH 7.0 
Semi-synthetic analogue of 
human insulin ProB26-DTI
1.70
 2.59
1UZ9 1.26 Crystallographic and solution 
studies of N-lithocholyl 
insulin: a new generation of 
prolonged acting insulins 
1.60
          1ZEH 1.28 Structure of insulin 1.50
1OS4 1.34 Dehydrated T6 human 
insulin at 295 K
microgravity 
2.25
3ZS2 1.37 TyrB25,NMEPheB26,LysB
28,ProB29-insulin 
analogue crystal structure 
1.97
1W8P 1.41 Structural properties of the 
B25Tyr-NME-B26he 
insulin mutant 
2.08
2G56 1.70 Crystal structure of human 
insulin-degrading enzyme 
in complex with insulin B 
chain
2.20
3UTT
 
1.72 1E6-A*0201-
ALWGPDPAAA Complex, 
Monoclinic
2.60
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3UTQ 1E6-A*0201-
ALWGPDPAAA Complex, 
Monoclinic
1.67
2WC0 1.81 Crystal structure of human 
insulin degrading enzyme 
in complex with iodinated 
insulin
2.80
2WBY 1.89 Crystal structure of human 
insulin degrading enzyme 
in complex with iodinated 
insulin
2.60
2G54 1.90 Crystal structure of Zn-
bound human insulin-
degrading enzyme in 
complex with insulin B 
chain
02.25.00
3UTS  2.02 1E6-A*0201-
ALWGPDPAAA Complex, 
Monoclinic 
2.71
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FURTHER ACTIVITIES
Further  activities  that  have  been  made  during  the  PhD  thesis  include 
attendances to international conferences (both as poster presenter and oral 
speaker). Moreover, four crystallographic protein structures have been done 
and deposited in PDB data-bank. 
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Further publications  have been made during the Medical Degree and the 
joint Italian-Russian Master.
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based on a search of the Google Scholar Citation Index database, by the  
number of articles published in the previous two years (2010 and 2011). 
A = the number of times, articles published in 2010 and 2011, which were  
cited by indexed journals during 2012 
B = the total number of ”citable items” published by that journal in 2010  
and 2011. 
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